Cancer Research and Treatment

Original Articles

Zolbetuximab Plus Chemotherapy as First-Line Treatment in Patients with Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: Korean Population Subgroup—Combined Efficacy and Safety Analysis from SPOTLIGHT and GLOW: Keun-Wook Lee, Sang Cheul Oh, Jong Gwang Kim, Sun Jin Sym, Byoung Yong Shim, Seok Yun Kang, In-Ho Kim, Jwa Hoon Kim, Hong Jae Chon, Sang-Hee Cho, Eun-Kee Song, Do-Youn Oh, Jin-Soo Kim, Young Iee Park, Won Ki Kang, Hyung-Don Kim, Janise Lee, Miri Yi, Min-Hee Ryu; Received August 28, 2025 Accepted December 4, 2025 Published online December 5, 2025; DOI: https://doi.org/10.4143/crt.2025.935 [Accepted]

Abstract PDF: Purpose
The phase 3 SPOTLIGHT and GLOW trials, in patients with claudin 18 isoform 2–positive, human epidermal growth factor receptor 2–negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) and overall survival (OS) with first-line zolbetuximab plus chemotherapy versus placebo plus chemotherapy. This analysis evaluated efficacy and safety in the Korean subgroup from SPOTLIGHT and GLOW.
Materials and Methods
Patients were randomized 1:1 to receive zolbetuximab plus chemotherapy or placebo plus chemotherapy (mFOLFOX6 [modified folinic acid, 5-fluorouracil, and oxaliplatin] or CAPOX [capecitabine and oxaliplatin]). Primary endpoint was PFS, assessed per RECIST v1.1 by independent review committee. Other efficacy and safety parameters were assessed.
Results
The Korean subgroup consisted of 49 patients in the zolbetuximab group and 47 in the placebo group. Median PFS (95% confidence interval [CI]) was 12.3 months (7.3-15.3), and median OS was 30.5 months (16.1-45.5) with zolbetuximab versus 8.1 months (4.2-10.4) and 15.8 months (11.8-19.7) with placebo, respectively. Most common TEAEs in patients who received zolbetuximab versus placebo were nausea (79.6% vs. 53.2%), vomiting (55.1% vs. 21.3%), and decreased appetite (53.1% vs. 23.4%). Treatment-related TEAEs led to discontinuation of zolbetuximab and placebo in 4.1% and 2.1% of patients, respectively.
Conclusion
Zolbetuximab plus chemotherapy demonstrated favorable PFS and OS versus placebo plus chemotherapy in the Korean subgroup, with numerically greater efficacy compared with the overall pooled population. This may be potentially attributable to low rates of zolbetuximab discontinuation and toxicity management.

48 View
7 Download

Extracellular Vesicle-Derived Adenosine as a Diagnostic Metabolic Biomarker for Pancreatic Ductal Adenocarcinoma: Tao Xia, Wenhui Ouyang, Jie Wang, Jinjing Wang, Yiping Mou, Zhengquan Yang, Hezhi Fang, Shanying Gui; Received May 12, 2025 Accepted September 11, 2025 Published online September 24, 2025; DOI: https://doi.org/10.4143/crt.2025.510 [Accepted]

Abstract PDF: Purpose
Current non-invasive diagnostic tools for pancreatic ductal adenocarcinoma (PDAC) exhibit limited sensitivity and specificity. This study aimed to identify more accurate plasma biomarkers by profiling extracellular vesicles (EVs), which are enriched in tumor-derived metabolites and proteins.
Materials and Methods
Plasma samples were collected under strict fasting and standardized processing protocols from patients diagnosed with PDAC, chronic pancreatitis (CP), and tumor-free controls (Ctrl). EVs were isolated from these plasma samples and subjected to comprehensive metabolomic and proteomic profiling to identify disease-specific biomarkers.
Results
A biomarker panel comprising adenosine, adenine, and N-acetylneuraminate (AAN) demonstrated outstanding diagnostic performance, achieving an area under the receiver operating characteristic curve (AUC) of 0.968 (95% CI: 0.92–1.00). At a fixed specificity of 96.8%, the panel yielded a sensitivity of 95.0% (95% CI: 85.0%–100.0%), significantly reducing the classification error from 30% with CA19-9 to 5% with the AAN panel. Among individual markers, adenosine alone showed high diagnostic power (AUC=0.952), correlating with increased expression of 5′-nucleotidase ecto (NT5E), indicative of elevated extracellular purine metabolism. Importantly, these features were unique to the EV compartment and outperformed markers derived from total plasma metabolite profiles.
Conclusion
The integration of EV metabolomics and proteomics revealed enhanced purine metabolism, particularly elevated extracellular adenosine, as a distinctive hallmark of PDAC. EV-derived adenosine emerges as a highly promising non-invasive biomarker with superior diagnostic accuracy compared to CA19-9.

505 View
51 Download

Lung and Thoracic cancer

Lipid Metabolism Related Gene ACSL3 as a Biomarker for Predicting Immunotherapy Outcomes in Lung Adenocarcinoma: Taiping He, Jinhan Hu, Haoyue Guo, Meng Diao, Yuanyuan Wang, Yuhan Wu, Lei Cheng, Chao Zhao, Xuefei Li, Caicun Zhou; Cancer Res Treat. 2025;57(4):1000-1018. Published online January 20, 2025; DOI: https://doi.org/10.4143/crt.2024.1119

Abstract PDF Supplementary Material PubReader ePub

Purpose
Investigate the role of lipid metabolism in the tumor immune microenvironment (TIME) of lung adenocarcinoma (LUAD) and identify vital lipid metabolism-related genes (LMRGs) that contribute to immunotherapy outcomes.
Materials and Methods
One thousand one hundred thirty LUAD patients were acquired utilizing public databases. Multiple algorithms were used to analyze the contribution of lipid metabolism in TIME. Importantly, cell lines, clinical samples (52 patients in surgery cohort and 36 in immunotherapy cohort), animal models, RNA sequencing (RNA-seq), experiments in protein and mRNA levels were conducted for identifying and validating key biomarker in LUAD immunotherapy.
Results
A prognostic signature comprising 33 LMRGs was developed and validated as an effective predictor of prognosis and TIME, with a C-index of 0.766 (95% confidence interval, 0.729 to 0.804). Additionally, we identified acyl-CoA synthetase long-chain family member 3 (ACSL3) as a potential biomarker for immunotherapy prognosis. The expression of ACSL3 was verified in 88 clinical tissues from LUAD patients, which indicated that elevated ACSL3 expression was correlated with worse progression-free survival (p < 0.001) and overall survival (p=0.008). Subsequent experiments revealed that knockdown of ACSL3 in vivo enhanced the efficacy of immunotherapy, potentially through increasing interferon-α secretion, as indicated by bulk RNA-seq and enzyme-linked immunosorbent assay analysis, thereby promoting the infiltration of antitumor immune cells.
Conclusion
The study established a model that accurately predicts immunotherapy response, prognosis, and TIME dynamics in LUAD patients. Notably, the pivotal role of ACSL3 in driving tumor progression and immune evasion was uncovered, offering novel insights into the optimization of immunotherapy strategies for LUAD.

Citations

Citations to this article as recorded by

Lipid Metabolism Reprogramming in Cancer: Insights into Tumor Cells and Immune Cells Within the Tumor Microenvironment
Rundong Liu, Chendong Wang, Zhen Tao, Guangyuan Hu
Biomedicines.2025; 13(8): 1895. CrossRef
Independent validation of lung adenocarcinoma prognostic risk scores incorporating cholesterol and estrogen metabolism related transcriptional biomarkers
Qian Zhu, Yuemei Zhang, Jian Ma, Yongjia Li, Hongya Liu, Zhongwen Gong, Ming Du, Xuemei Lian
Scientific Reports.2025;[Epub] CrossRef

3,258 View
165 Download
2 Web of Science
2 Crossref

Long-term Survival Outcomes of Surgical Resection for Lung Adenocarcinoma with Intraoperatively Diagnosed Pleural Metastasis: Target Treatment Era: Yelee Kwon, Jae Kwang Yun, Geun Dong Lee, Se Hoon Choi, Yong-Hee Kim, Hyeong Ryul Kim; Cancer Res Treat. 2025;57(4):981-988. Published online December 30, 2024; DOI: https://doi.org/10.4143/crt.2024.993

Abstract PDF Supplementary Material PubReader ePub: Purpose
This study aimed to evaluate the clinical impact of main tumor resection on long-term survival compared with pleural biopsy alone in patients with lung adenocarcinoma who were intraoperatively diagnosed with pleural metastasis.
Materials and Methods
A total of 176 patients with adenocarcinoma who had unexpected pleural metastasis detected during surgery from 2002 to 2021 were retrospectively analyzed. Each surgeon decided whether to perform main tumor resection or pleural biopsy alone.
Results
The patients were grouped based on the surgical approaches: main tumor resection (resection group; n=83) and pleural biopsy only (O&C group; n=93). The resection group had better overall survival (OS; 10-year survival, 27.9% vs. 9.4%; median survival, 68.3 vs. 36.6 months; p < 0.01) and locoregional progression-free survival (10-year survival, 12.5% vs. 7.1%; median survival, 19.6 vs. 10.6 months; p < 0.01) than the O&C group. Similar results were found for OS in patients who received tyrosine kinase inhibitors (TKIs) as first-line therapy (10-year survival, 49.2% vs. 15.0%; median survival, 72.2 vs. 45.4 months; p=0.03), patients who did not undergo TKIs treatment (10-year survival, 29.4% vs. 9.2%; median survival, 82.4 vs. 23.8 months; p < 0.01), and patients with positive target gene mutation (10-year survival, 31.7% vs. 10.1%; median survival, 72.2 vs. 33.7 months; p < 0.01). In multivariate analysis, pleural biopsy only (hazard ratio, 1.73; p=0.04) was a significant predictor of OS.
Conclusion
Main tumor resection can improve survival in patients with lung adenocarcinoma who had unexpected pleural metastasis during operation.

3,325 View
81 Download

Gastrointestinal cancer

Predictive Value of the nProfiler 1 Assay for the Efficacy of Adjuvant S-1–Based Doublet Chemotherapy in Stage III Gastric Cancer: A Post-Hoc Analysis of a Randomized Phase III Trial: Dong Ki Lee, Choong-kun Lee, Hyo Song Kim, Sun Jin Sym, Dae Young Zang, Ki Hyang Kim, Joo Han Lim, Hae Su Kim, Kyung Hee Lee, Heon Yung Gee, Sun Young Rha, Hyunki Kim, Minkyu Jung; Cancer Res Treat. 2025;57(3):770-780. Published online November 12, 2024; DOI: https://doi.org/10.4143/crt.2024.705

Abstract PDF Supplementary Material PubReader ePub: Purpose
The nProfiler 1 Stomach Cancer Assay (nProfiler1), designed to predict responses to fluorouracil-based adjuvant chemotherapy, measures the expression of four gastric cancer target genes (GZMB, WARS, SFRP4, and CDX1). The randomized phase III POST trial aimed to compare the efficacies of two adjuvant S-1-based doublet chemotherapies: S-1 plus cisplatin (SP) and S-1 plus docetaxel (DS). This study aimed to validate the nProfiler1 assay using a distinct cohort from the POST trial.
Materials and Methods
The nProfiler1 assay stratifies patients into three groups (low-risk, intermediate-risk, and high-risk) using the prognostic single-patient classifier and two groups (chemotherapy-benefit and no-benefit) using the predictive single-patient classifier. The nProfiler1 assay was applied to formalin-fixed paraffin-embedded slides obtained from the POST trial. Disease-free survival (DFS) and overall survival (OS), including 5-year survival rates, were calculated for the enrolled patients.
Results
Of the 153 patients in the POST trial, 118 were included in the post-hoc analysis. With a median follow-up of 57.9 months, no significant difference in DFS or OS was observed between the SP and DS groups. The prognostic single-patient classifier predicted the OS in the SP group (p=0.043) but not in the DS group (p=0.594). The chemotherapy-benefit group exhibited numerically longer DFS than the no-benefit group in the SP and DS groups.
Conclusion
The nProfiler1 assay offers valuable insights into the prognosis and efficacy of adjuvant chemotherapy based on fluorouracil plus platinum doublet regimens but not docetaxel-containing regimens. Further validation with larger patient cohorts and different regimens is warranted.

2,883 View
145 Download

Genitourinary cancer

Clear Cell Adenocarcinoma of Urethra: Clinical and Pathologic Implications and Characterization of Molecular Aberrations: Boram Song, Seok Hyun Lee, Jeong Hwan Park, Kyung Chul Moon; Cancer Res Treat. 2024;56(1):280-293. Published online September 11, 2023; DOI: https://doi.org/10.4143/crt.2023.577

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to evaluate the molecular features of clear cell adenocarcinoma (CCA) of the urinary tract and investigate its pathogenic pathways and possible actionable targets.
Materials and Methods
We retrospectively collected the data of patients with CCA between January 1999 and December 2016; the data were independently reviewed by two pathologists. We selected five cases of urinary CCA, based on the clinicopathological features. We analyzed these five cases by whole exome sequencing (WES) and subsequent bioinformatics analyses to determine the mutational spectrum and possible pathogenic pathways.
Results
All patients were female with a median age of 62 years. All tumors were located in the urethra and showed aggressive behavior with disease progression. WES revealed several genetic alterations, including driver gene mutations (AMER1, ARID1A, CHD4, KMT2D, KRAS, PBRM1, and PIK3R1) and mutations in other important genes with tumor-suppressive and oncogenic roles (CSMD3, KEAP1, SMARCA4, and CACNA1D). We suggest putative pathogenic pathways (chromatin remodeling pathway, mitogen-activated protein kinase signaling pathway, phosphoinositide 3-kinase/AKT/mammalian target of rapamycin pathway, and Wnt/β-catenin pathway) as candidates for targeted therapies.
Conclusion
Our findings shed light on the molecular background of this extremely rare tumor with poor prognosis and can help improve treatment options.

Citations

Citations to this article as recorded by

Urethral clear cell adenocarcinoma in an adult female: A rare case report
Yacob Sheiferawe Seman, Michael Teklehaimanot Abera, Fadil Nuredin Abrar, Tesfaye Kebede Legesse, Mesfin Asefa Tola, Tsiyon Nigusie Alemu
Urology Case Reports.2025; 58: 102882. CrossRef
Two rare cases of primary clear cell adenocarcinoma of the urethra: clinical experience, case report and literature review
Bohao Jiang, Jiyuan Hu, Benqiao Wang, Xujia Liu, Ling Tong, Yitong Xu, Hao Zhang
Frontiers in Oncology.2025;[Epub] CrossRef
Comprehensive Molecular, Pathological, and Clinical Characterization of Clear Cell Adenocarcinoma of the Urinary Tract
Rayan Rammal, Florestan J. Koll, Ziyu Chen, Jacob E. Tallman, Syed Muneeb Alam, Jordan E. Eichholz, Walid Chatila, Tejiri Agbamu, Andrew T. Lenis, Merve Basar, Cansu Yol, Jie-Fu Chen, Judy Sarungbam, Ying-Bei Chen, Anuradha Gopalan, Samson W. Fine, Satish
Modern Pathology.2025; 38(10): 100821. CrossRef
Association between CACNA1D polymorphisms and hypospadias in a southern Chinese population
Ye He, Binyao Li, Xinying Zhao, Lingling Pan, Yanqing Liu, Chaoting Lan, Fuming Deng, Wen Fu, Yan Zhang, Xiaoyu Zuo
Journal of Pediatric Urology.2024; 20(3): 438.e1. CrossRef
The L‐type calcium channel CaV1.3: A potential target for cancer therapy
Xuerun Liu, Boqiang Shen, Jingyi Zhou, Juan Hao, Jianliu Wang
Journal of Cellular and Molecular Medicine.2024;[Epub] CrossRef

5,658 View
213 Download
6 Web of Science
5 Crossref

Lung and Thoracic cancer

Aggressive Local Ablative Radiotherapy Mitigates Progression Risk in Oligometastatic Lung Adenocarcinoma: Gowoon Yang, Kyung Hwan Kim, Chang Geol Lee, Min Hee Hong, Hye Ryun Kim, Yeona Cho, Hong In Yoon; Cancer Res Treat. 2024;56(1):115-124. Published online August 29, 2023; DOI: https://doi.org/10.4143/crt.2023.600

Abstract PDF Supplementary Material PubReader ePub: Purpose
This study aimed to determine the role of local ablative radiotherapy (LART) in oligometastatic/oligoprogressive lung adenocarcinoma.
Materials and Methods
Patients (n=176) with oligometastatic lung adenocarcinoma treated with LART were identified, and those treated with LART at the initial diagnosis of synchronous oligometastatic disease (OMD group) or treated with LART when they presented with repeat oligoprogression (OPD group) were included.
Results
In the OMD group (n=54), the 1- and 3-year progression-free survival (PFS) were 50.9% and 22.5%, respectively, whereas the 1- and 3-year overall survival in the OPD group were 75.9% and 58.1%, respectively. Forty-one patients (75.9%) received LART at all gross disease sites. Tyrosine kinase inhibitor (TKI) use and all-metastatic site LART were significant predictors of higher PFS (p=0.018 and p=0.046, respectively). In patients treated with TKIs at the time of LART (n=23) and those treated with all-metastatic site LART, the 1-year PFS was 86.7%, while that of patients not treated with all-metastatic site LART was 37.5% (p=0.006). In the OPD group (n=122), 67.2% of the patients (n=82) maintained a systemic therapy regimen after LART. The cumulative incidence of changing systemic therapy was 39.6%, 62.9%, and 78.5% at 6 months, 1 year, and 2 years after LART, respectively.
Conclusion
Aggressive LART can be an option to improve survival in patients with oligometastatic disease. Patients with synchronous oligometastatic disease receiving TKI and all-metastatic site LART may have improved PFS. In patients with repeat oligoprogression, LART might potentially extend survival by delaying the need to change the systemic treatment regimen.

4,182 View
201 Download

Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma: Jae Seok Lee, Eun Kyung Kim, Kyung A Kim, Hyo Sup Shim; Cancer Res Treat. 2024;56(1):104-114. Published online July 24, 2023; DOI: https://doi.org/10.4143/crt.2023.728

Abstract PDF Supplementary Material PubReader ePub

Purpose
We investigated the clinical impact of genomic and pathway alterations in stage I epidermal growth factor receptor (EGFR)–mutant lung adenocarcinomas, which have a high recurrence rate despite complete surgical resection.
Materials and Methods
Out of the initial cohort of 257 patients with completely resected stage I EGFR-mutant lung adenocarcinoma, tumor samples from 105 patients were subjected to analysis using large-panel next-generation sequencing. We analyzed 11 canonical oncogenic pathways and determined the number of pathway alterations (NPA). Survival analyses were performed based on co-occurring alterations and NPA in three patient groups: all patients, patients with International Association for the Study of Lung Cancer (IASLC) pathology grade 2, and patients with recurrent tumors treated with EGFR–tyrosine kinase inhibitor (TKI).
Results
In the univariate analysis, pathological stage, IASLC grade, TP53 mutation, NPA, phosphoinositide 3-kinase pathway, p53 pathway, and cell cycle pathway exhibited significant associations with worse recurrence-free survival (RFS). Moreover, RPS6KB1 or EGFR amplifications were linked to a poorer RFS. Multivariate analysis revealed that pathologic stage, IASLC grade, and cell cycle pathway alteration were independent poor prognostic factors for RFS (p=0.002, p < 0.001, and p=0.006, respectively). In the grade 2 subgroup, higher NPA was independently associated with worse RFS (p=0.003). Additionally, in patients with recurrence treated with EGFR-TKIs, co-occurring TP53 mutations were linked to shorter progression-free survival (p=0.025).
Conclusion
Genomic and pathway alterations, particularly cell cycle alterations, high NPA, and TP53 mutations, were associated with worse clinical outcomes in stage I EGFR-mutant lung adenocarcinoma. These findings may have implications for risk stratification and the development of new therapeutic strategies in early-stage EGFR-mutant lung cancer patients.

Citations

Citations to this article as recorded by

Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA
Yoshihiko Taniguchi, Akihiro Tamiya, Mitsuo Osuga, Shun-ichi Isa, Keiichi Nakamura, Yasuyuki Mizumori, Tsutomu Shinohara, Hidetoshi Yanai, Katsumi Nakatomi, Masahide Oki, Masahide Mori, Tomohito Kuwako, Koji Yamazaki, Masahiro Shimada, Masahiko Ando, Yasu
Investigational New Drugs.2025;[Epub] CrossRef
A Novel CLTC::RPS6KB1 Fusion in a Poorly Differentiated Carcinoma Involving the Lung and Mediastinum
Mitchell Zhao, Nicholas Protopsaltis, Mina Sabet, Shulei Sun, Grace Lin, Farnaz Hasteh, Wei Song
International Journal of Surgical Pathology.2025; 33(6): 1526. CrossRef

4,917 View
218 Download
3 Web of Science
2 Crossref

Gastrointestinal cancer

Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma: Kum Hei Ryu, Sunhwa Park, Jung Won Chun, Eunhae Cho, Jongmun Choi, Dong-Eun Lee, Hyoeun Shim, Yun-Hee Kim, Sung-Sik Han, Sang-Jae Park, Sang Myung Woo, Sun-Young Kong; Cancer Res Treat. 2023;55(4):1303-1312. Published online April 3, 2023; DOI: https://doi.org/10.4143/crt.2023.291

Abstract PDF Supplementary Material PubReader ePub

Purpose
The genetic attribution for pancreatic ductal adenocarcinoma (PDAC) has been reported as 5%-10%. However, the incidence of germline pathogenic variants (PVs) in Korean PDAC patients has not been thoroughly investigated. Therefore, we studied to identify the risk factors and prevalence of PV for future treatment strategies in PDAC.
Materials and Methods
Total of 300 (155 male) patients with a median age of 65 years (range, 33 to 90 years) were enrolled in National Cancer Center in Korea. Cancer predisposition genes, clinicopathologic characteristics, and family history of cancer were analyzed.
Results
PVs were detected in 20 patients (6.7%, median age 65) in ATM (n=7, 31.8%), BRCA1 (n=3, 13.6%), BRCA2 (n=3), and RAD51D (n=3). Each one patient showed TP53, PALB2, PMS2, RAD50, MSH3, and SPINK1 PV. Among them, two likely PVs were in ATM and RAD51D, respectively. Family history of various types of cancer including pancreatic cancer (n=4) were found in 12 patients. Three patients with ATM PVs and a patient with three germline PVs (BRCA2, MSH3, and RAD51D) had first-degree relatives with pancreatic cancer. Familial pancreatic cancer history and PVs detection had a significant association (4/20, 20% vs. 16/264, 5.7%; p=0.035).
Conclusion
Our study demonstrated that germline PVs in ATM, BRCA1, BRCA2, and RAD51D are most frequent in Korean PDAC patients and it is comparable to those of different ethnic groups. Although this study did not show guidelines for germline predisposition gene testing in patients with PDAC in Korea, it would be emphasized the need for germline testing for all PDAC patients.

Citations

Citations to this article as recorded by

FOXM1 promotes malignant biological behavior and metabolic reprogramming by targeting SPINK1 in hepatocellular carcinoma and affecting the p53 pathway
Xu Ding, Jinjun Shi, Zhengqing Lei, Guoqing Wang, Chenchun Fu, Xiangyu Su, Guangyu Zhu
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2025; 1871(3): 167673. CrossRef
Mutant KRAS and GATA6 Stratify Survival in Patients Treated with Chemotherapy for Pancreatic Adenocarcinoma: A Prospective Cohort Study
Jung Won Chun, Dong-eun Lee, Nayoung Han, SooBeen Heo, Hyeji Kim, Mi Rim Lee, Hyeong Min Park, Sung-Sik Han, Sang-Jae Park, Tae Hyun Kim, Woo Jin Lee, Yun-Hee Kim, Sun-Young Kong, Sang Myung Woo
Cancers.2025; 17(5): 896. CrossRef
Scenario of endometrial cancer in Asian countries: epidemiology, risk factors and challenges
Sayeeda Sultana, Rehana Parveen
International Journal Of Community Medicine And Public Health.2025; 12(6): 2921. CrossRef
MLH1 Inhibits Metastatic Potential of Pancreatic Ductal Adenocarcinoma via Downregulation of GPRC5C
Wen-Jing Liu, Jun Lu, Wei-Xun Zhou, Jian-Zhou Liu, Li Zhou
Laboratory Investigation.2024; 104(9): 102107. CrossRef
Clinical Significance of PALB2 Pathogenic Germline Variant
Min-Chae Kang, R.N., Jong Eun Park, Mi-Ae Jang, Dongju Won, Boyoung Park, Seeyoun Lee, Dong Ock Lee, Kum Hei Ryu, Yoon-Jung Chang, Sun-Young Kong
Laboratory Medicine Online.2024; 14(4): 311. CrossRef
Prevalence Estimation of the PALB2 Germline Variant in East Asians and Koreans through Population Database Analysis
Jong Eun Park, Min-Chae Kang, Taeheon Lee, Eun Hye Cho, Mi-Ae Jang, Dongju Won, Boyoung Park, Chang-Seok Ki, Sun-Young Kong
Cancers.2024; 16(19): 3318. CrossRef
Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review
Antonino Pantaleo, Giovanna Forte, Candida Fasano, Martina Lepore Signorile, Paola Sanese, Katia De Marco, Elisabetta Di Nicola, Marialaura Latrofa, Valentina Grossi, Vittoria Disciglio, Cristiano Simone
Cancers.2023; 16(1): 56. CrossRef

6,457 View
277 Download
6 Web of Science
7 Crossref

Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX: So Heun Lee, Dae Wook Hwang, Changhoon Yoo, Kyu-pyo Kim, Sora Kang, Jae Ho Jeong, Dongwook Oh, Tae Jun Song, Sang Soo Lee, Do Hyun Park, Dong Wan Seo, Jin-hong Park, Ki Byung Song, Jae Hoon Lee, Woohyung Lee, Yejong Park, Bong Jun Kwak, Heung-Moon Chang, Baek-Yeol Ryoo, Song Cheol Kim; Cancer Res Treat. 2023;55(3):956-968. Published online February 27, 2023; DOI: https://doi.org/10.4143/crt.2022.409

Abstract PDF Supplementary Material PubReader ePub

Purpose
The benefit of adjuvant chemotherapy following curative-intent surgery in pancreatic ductal adenocarcinoma (PDAC) patients who had received neoadjuvant FOLFIRINOX is unclear. This study aimed to assess the survival benefit of adjuvant chemotherapy in this patient population.
Materials and Methods
This retrospective study included 218 patients with localized non-metastatic PDAC who received neoadjuvant FOLFIRINOX and underwent curative-intent surgery (R0 or R1) between January 2017 and December 2020. The association of adjuvant chemotherapy with disease-free survival (DFS) and overall survival (OS) was evaluated in overall patients and in the propensity score matched (PSM) cohort. Subgroup analysis was conducted according to the pathology-proven lymph node status.
Results
Adjuvant chemotherapy was administered to 149 patients (68.3%). In the overall cohort, the adjuvant chemotherapy group had significantly improved DFS and OS compared to the observation group (DFS: median, 13.8 months [95% confidence interval (CI), 11.0 to 19.1] vs. 8.2 months [95% CI, 6.5 to 12.0]; p < 0.001; and OS: median, 38.0 months [95% CI, 32.2 to not assessable] vs. 25.7 months [95% CI, 18.3 to not assessable]; p=0.005). In the PSM cohort of 57 matched pairs of patients, DFS and OS were better in the adjuvant chemotherapy group than in the observation group (p < 0.001 and p=0.038, respectively). In the multivariate analysis, adjuvant chemotherapy was a significant favorable prognostic factor (vs. observation; DFS: hazard ratio [HR], 0.51 [95% CI, 0.36 to 0.71; p < 0.001]; OS: HR, 0.45 [95% CI, 0.29 to 0.71; p < 0.001]).
Conclusion
Among PDAC patients who underwent surgery following neoadjuvant FOLFIRINOX, adjuvant chemotherapy may be associated with improved survival. Randomized studies should be conducted to validate this finding.

Citations

Citations to this article as recorded by

Prognostic factors in localized pancreatic ductal adenocarcinoma after neoadjuvant therapy and resection: a systematic review and meta-analysis
Ammar A Javed, Alyssar Habib, Omar Mahmud, Asad Saulat Fatimi, Mahip Grewal, Nabiha Mughal, Jin He, Christopher L Wolfgang, Lois Daamen, Marc G Besselink
JNCI: Journal of the National Cancer Institute.2025; 117(5): 840. CrossRef
Chemotherapy hypersensitivity: Current insights and novel desensitization strategies
Gordon K.H. Chu, Andy K.C. Kan, James K.Y. Hooi, Hye-Ryun Kang, Philip H. Li
Journal of Allergy and Hypersensitivity Diseases.2025; 6: 100042. CrossRef
Radiotherapy of pancreatic cancer patients. Past and present: a review
M. A. Ilin, S. D. Trotsenko, M. V. Podolskaya
Diagnostic radiology and radiotherapy.2025; 16(2): 20. CrossRef
The survival effect of neoadjuvant therapy and neoadjuvant plus adjuvant therapy on pancreatic ductal adenocarcinoma patients with different TNM stages: a propensity score matching analysis based on the SEER database
Hao Hu, Yang Xu, Qiang Zhang, Yuan Gao, Zhenyu Wu
Expert Review of Anticancer Therapy.2024; 24(6): 467. CrossRef
Neoadjuvant treatment of pancreatic ductal adenocarcinoma: Whom, when and how
Nebojsa Manojlovic, Goran Savic, Stevan Manojlovic
World Journal of Gastrointestinal Surgery.2024; 16(5): 1223. CrossRef
Case Study on Analysing the Early Disease Detection of Pancreatic Ductal Adenocarcinoma in Korean Association for Clinical Oncology
Sijithra Ponnarassery Chandran, N. Santhi
American Journal of Clinical Oncology.2024; 47(10): 475. CrossRef
Evaluating the benefits of adjuvant chemotherapy in patients with pancreatic cancer undergoing radical pancreatectomy after neoadjuvant therapy—a systematic review and meta-analysis
Jiahao Wu, Yike Zhang, Haodong Wang, Wenyi Guo, Chengqing Li, Yichen Yu, Han Liu, Feng Li, Lei Wang, Jianwei Xu
Frontiers in Oncology.2024;[Epub] CrossRef

7,268 View
178 Download
6 Web of Science
7 Crossref

Lung and Thoracic cancer

Selection Strategies and Practical Application of BRAF V600E-Mutated Non–Small Cell Lung Carcinoma: Inwoo Hwang, Yoon-La Choi, Hyunwoo Lee, Soohyun Hwang, Boram Lee, Hobin Yang, Chaithanya Chelakkot, Joungho Han; Cancer Res Treat. 2022;54(3):782-792. Published online November 23, 2021; DOI: https://doi.org/10.4143/crt.2021.843

Abstract PDF Supplementary Material PubReader ePub

Purpose
The incidence of BRAF V600E mutation in non-small cell lung carcinoma (NSCLC) is lower than 2%, which poses difficulties in finding legitimate patients for targeted therapy. We investigated the predictive factors pertaining to BRAF V600E and the effectiveness of the VE1 antibody as a screening method for patient selection.
Materials and Methods
The study was designed into two steps. In a first group, BRAF-mutated NSCLCs were identified from sequencing data to determine the features of BRAF V600E mutation. The results of the first group helped the collection of adenocarcinomas with a papillary or micropapillary pattern but without EGFR or ALK alterations as a second group so that the frequency of BRAF V600E mutation could be calculated. The sensitivity and specificity of the VE1 were compared with BRAF V600E status.
Results
Among 39 BRAF-mutated NSCLCs in the first group, 20 (51%) were V600E. BRAF V600E mutation was more common in female patients and showed no significant correlation with smoking status. Nineteen cases were adenocarcinomas without EGFR and ALK alterations. The most common patterns of invasion were papillary and micropapillary along with central fibrosis. The sensitivity and specificity of the VE1 were 90.0% and 92.3%, respectively. In the second group, 6.7% of cases were VE1-positive, indicating that the prevalence was significantly higher than that reported in previous studies (0.3-1.8%).
Conclusion
BRAF V600E-mutated NSCLCs could be enriched with the application of clinicopathologic parameters, which are not perfect. Therefore, additional VE1 immunohistochemistry may be useful as a screening method.

Citations

Citations to this article as recorded by

High-Quality Samples for Next-Generation Sequencing and PD-L1 Assessment in Non-Small Cell Lung Cancer: The Role of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration
Marta Rodríguez González, Juan Montero, José Sayagués, Tamara Sánchez, Jonnathan Ruiz, Miguel Iglesias Heras, María Rivas Marcos, Mar Abad, Rosa Cordovilla Pérez
Diagnostics.2025; 15(9): 1064. CrossRef
The rapidly changing field of predictive biomarkers of non-small cell lung cancer
László József Tóth, Attila Mokánszki, Gábor Méhes
Pathology and Oncology Research.2024;[Epub] CrossRef
BRAF V600E Mutation of Non-Small Cell Lung Cancer in Korean Patients
Hyo Yeong Ahn, Chang Hun Lee, Min Ki Lee, Jung Seop Eom, Yeon Joo Jeong, Yeong Dae Kim, Jeong Su Cho, Jonggeun Lee, So Jeong Lee, Dong Hoon Shin, Ahrong Kim
Medicina.2023; 59(6): 1085. CrossRef
The Impact of Liquid Biopsies Positive for EGFR Mutations on Overall Survival in Non-Small Cell Lung Cancer Patients
Jonnathan Roldan Ruiz, Marta Fuentes Gago, Luis Chinchilla Tabora, Idalia Gonzalez Morais, José Sayagués, Mar Abad Hernández, Maria Cordovilla Pérez, Maria Ludeña de la Cruz, Edel del Barco Morillo, Marta Rodriguez Gonzalez
Diagnostics.2023; 13(14): 2347. CrossRef
Usefulness of BRAF VE1 immunohistochemistry in non–small cell lung cancers: a multi-institutional study by 15 pathologists in Korea
Sunhee Chang, Yoon-La Choi, Hyo Sup Shim, Geon Kook Lee, Seung Yeon Ha
Journal of Pathology and Translational Medicine.2022; 56(6): 334. CrossRef

7,830 View
174 Download
5 Web of Science
5 Crossref

Histologic Changes in Non–Small Cell Lung Cancer under Various Treatments: A Comparison of Histology and Mutation Status in Serial Samples: Chang Gok Woo, Seung-Myoung Son, Ho-Chang Lee, Hye Sook Han, Ki Hyeong Lee, Dohun Kim, Eung-Gook Kim, Ok-Jun Lee; Cancer Res Treat. 2022;54(3):737-743. Published online September 24, 2021; DOI: https://doi.org/10.4143/crt.2021.773

Abstract PDF Supplementary Material PubReader ePub

Purpose
Histologic change is a resistant mechanism in lung cancer. The most common histological change is the switch from adenocarcinoma (AdenoCa) to small cell carcinoma (SCC) against to tyrosine kinase inhibitors (TKI). However, it is not clear whether other treatment modalities are involved in the histologic changes.
Materials and Methods
We investigated histological changes in eight cases, after various treatments, and compared the molecular profiles between primary tumors and changed tumors using exome sequencing where tissue was available.
Results
Three cases of AdenoCa that were changed into SCC retained the initial mutations after TKI and/or surgical treatment. After treatment with TKI and immunotherapy, an EGFR (epidermal growth factor receptor)-mutant AdenoCa changed to squamous cell carcinoma (SqCa). SqCa in a patient treated with surgery was changed into combined AdenoCa and SqCa. These two cases showed the same genetic variations between the two distinct non–small cell carcinomas (NSCC). Three patients experienced two histologic changes, which the changed tumors returned to its original subtype or changed to a combined tumor after treatments. Four cases showed combined histology in the first or second change.
Conclusion
The histology of NSCC can be changed to a single pattern or combined subtypes after various treatment modalities, and the phenotypic changes seem not fixed. Therefore, additional morphologic changes may occur regardless of their genetic status and types of treatments. To refine the new treatment strategy, consecutive repeated biopsies in progressive disease or recurrent tumor are necessary.

Citations

Citations to this article as recorded by

Patients outcomes in lung adenocarcinoma transforming to small-cell lung cancer after tyrosine kinase inhibitor therapy
Shuai Wang, Yongsen Wang, Xuan Wu, Li Yang, Xiaoju Zhang
World Journal of Surgical Oncology.2025;[Epub] CrossRef
Clinicopathologic features of histologic transformation in lung adenocarcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitors
Halim Song, Deokhoon Kim, Se Jin Jang, Hee Sang Hwang, Joon Seon Song
Annals of Diagnostic Pathology.2025; 77: 152478. CrossRef
Whole Exome Sequencing Study Identifies Distinct Characteristics of Transformed Small Cell Lung Cancer With EGFR Mutation Compared to De Novo Small Cell and Primary Non‐Small Cell Lung Cancers
Jinjing Tan, Dan Zhao, Qunhui Wang, Yanjing Peng, Jie Li, Xi Li, Nanying Che, Ying Hu, Hua Zheng
Cancer Medicine.2025;[Epub] CrossRef
Clinical application of microwave ablation combined with coaxial needle biopsy using different sequences for treating lung nodules suggestive of malignancy
Yibing Li, Xinyou Su, Ruobing Li, Jianqiang Zhao, Aimei Ouyang, Taiyang Zuo
International Journal of Hyperthermia.2025;[Epub] CrossRef
Quantitative radiomic analysis of computed tomography scans using machine and deep learning techniques accurately predicts histological subtypes of non-small cell lung cancer: A retrospective analysis
Suhrud Panchawagh, Arita Halder, Saloni Haldule, Vivek Sanker, Devansh Lalwani, Rachel Sequeria, Harshika Naik, Atman Desai
European Journal of Surgical Oncology.2025; 51(10): 110376. CrossRef
Prevalence of Histological Transformation in First-Line Osimertinib Non-Small Cell Lung Cancers: Case Series and Literature Review
Rebecca Sparavelli, Rossella Bruno, Alessandra Celi, Andrea Sbrana, Iacopo Petrini, Antonio Chella, Clara Ugolini, Greta Alì
International Journal of Molecular Sciences.2025; 26(21): 10462. CrossRef
Using ex vivo bioengineered lungs to model pathologies and screening therapeutics: A proof‐of‐concept study
Mohammadali Ahmadipour, Jorge Castilo Prado, Benyamin Hakak‐Zargar, Malik Quasir Mahmood, Ian M. Rogers
Biotechnology and Bioengineering.2024; 121(10): 3020. CrossRef
Noninvasive Lung Cancer Subtype Classification Using Tumor-Derived Signatures and cfDNA Methylome
Shuo Li, Wenyuan Li, Bin Liu, Kostyantyn Krysan, Steven M. Dubinett
Cancer Research Communications.2024; 4(7): 1738. CrossRef
Hepatoid Adenocarcinoma of the Lung: A Review of the Most Updated Literature and a Presentation of Three Cases
Alessandro Bonis, Andrea Dell’Amore, Vincenzo Verzeletti, Luca Melan, Giovanni Zambello, Chiara Nardocci, Giovanni Maria Comacchio, Federica Pezzuto, Fiorella Calabrese, Federico Rea
Journal of Clinical Medicine.2023; 12(4): 1411. CrossRef
Gene‐level dissection of chromosome 3q locus amplification in squamous cell carcinoma of the lung using the nCounter assay
Taesung Jeon, Uk Jeen Oh, Jaeyoung Min, Chungyeul Kim
Thoracic Cancer.2023; 14(26): 2635. CrossRef
Clinical Outcome of Stereotactic Body Radiotherapy in Patients with Early-Stage Lung Cancer with Ground-Glass Opacity Predominant Lesions: A Single Institution Experience
Jeong Yun Jang, Su Ssan Kim, Si Yeol Song, Young Seob Shin, Sei Won Lee, Wonjun Ji, Chang-Min Choi, Eun Kyung Choi
Cancer Research and Treatment.2023; 55(4): 1181. CrossRef
Challenges and Opportunities for Immunoprofiling Using a Spatial High-Plex Technology: The NanoString GeoMx® Digital Spatial Profiler
Sharia Hernandez, Rossana Lazcano, Alejandra Serrano, Steven Powell, Larissa Kostousov, Jay Mehta, Khaja Khan, Wei Lu, Luisa M. Solis
Frontiers in Oncology.2022;[Epub] CrossRef

8,692 View
224 Download
14 Web of Science
12 Crossref

The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma: Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J.W. Chen, Gee-Chen Chang; Cancer Res Treat. 2022;54(2):434-444. Published online August 2, 2021; DOI: https://doi.org/10.4143/crt.2021.671

Abstract PDF PubReader ePub

Purpose
The aim of this study was to investigate the efficacy of various epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma patients.
Materials and Methods
From August 2016 to October 2020, we enrolled advanced lung adenocarcinoma patients harboring exon 19 deletion or L858R receiving gefitinib, erlotinib and afatinib plus bevacizumab as the first-line treatment for the purposes of analysis.
Results
A total of 36 patients were included in the final analysis. Three patients received gefitinib, 17 received erlotinib, and 16 received afatinib combined with bevacizumab as the first-line treatment. The objective response rate was 77.8%, and disease control rate was 94.4%. The overall median progression-free survival (PFS) was 16.4 months, while the median PFS was 17.1 months in patients with exon 19 deletion, and 16.2 months in patients with L858R mutation (p=0.311). Regarding the use of different EGFR-TKIs, the median PFS was 17.1 months in the erlotinib group and 21.6 months in the afatinib group (p=0.617). In patients with brain metastasis at baseline, the median PFS was 18.9 months in the erlotinib group and 16.4 months in the afatinib group (p=0.747). Amongst patients harboring exon 19 deletion, the median PFS was 16.2 months in the erlotinib group and not-reached in the afatinib group (p=0.141). In patients with L858R mutation, the median PFS was 18.9 months in the erlotinib group and 16.2 months in the afatinib group (p=0.481).
Conclusion
Our research demonstrates that not only erlotinib combined with bevacizumab, but also afatinib plus bevacizumab as first-line treatment, provides solid clinical efficacy in advanced EGFR-mutant lung adenocarcinoma patients.

Citations

Citations to this article as recorded by

Efficacy and safety of targeted therapy combined with anti-angiogenesis treatment in brain metastases of non-small cell lung cancer: a systematic review and meta-analysis
Yin Pan, Qiaohua Gu
Lung Cancer.2025; 203: 108532. CrossRef
Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR‐mutated advanced non‐small‐cell lung
Chia‐Yu Kuo, Ming‐Ju Tsai, Jen‐Yu Hung, Mei‐Hsuan Lee, Kuan‐Li Wu, Yu‐Chen Tsai, Cheng‐Hao Chuang, Chung‐Wen Huang, Chin‐Ling Chen, Chih‐Jen Yang, Inn‐Wen Chong
The Kaohsiung Journal of Medical Sciences.2024; 40(5): 467. CrossRef
Scorpiones, Scolopendra and Gekko Inhibit Lung Cancer Growth and Metastasis by Ameliorating Hypoxic Tumor Microenvironment via PI3K/AKT/mTOR/HIF-1α Signaling Pathway
Qi-yuan Mao, Xue-qian Wang, Fei Lin, Ming-wei Yu, Hui-ting Fan, Qi Zheng, Lan-chun Liu, Chu-chu Zhang, Dao-rui Li, Hong-sheng Lin
Chinese Journal of Integrative Medicine.2024; 30(9): 799. CrossRef
Real-world clinical efficacy of bevacizumab biosimilar in patients with advanced non-small-cell lung cancer
Wei-Fan Ou, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Po-Hsin Lee, Kun-Chieh Chen, Yen-Hsiang Huang, Gee-Chen Chang, Tsung-Ying Yang
Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
Ruijian Li, Weiyi Li, Fang Zhang, Shanshan Li
European Journal of Medical Research.2023;[Epub] CrossRef
Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study
Wen-Chien Cheng, Yi-Cheng Shen, Chieh-Lung Chen, Wei-Chih Liao, Chia-Hung Chen, Hung-Jen Chen, Chih-Yen Tu, Te-Chun Hsia
Cancers.2023; 15(3): 642. CrossRef
Afatinib/bevacizumab/erlotinib

Reactions Weekly.2023; 1952(1): 32. CrossRef
Comprehensive analysis of prediction of the EGFR mutation and subtypes based on the spinal metastasis from primary lung adenocarcinoma
Ran Cao, Huanhuan Chen, Huan Wang, Yan Wang, E-Nuo Cui, Wenyan Jiang
Frontiers in Oncology.2023;[Epub] CrossRef
When to add anti-angiogenesis drugs to EGFR-mutated metastatic non–small cell lung cancer patients: a real-world study from Taiwan
Chieh-Lung Chen, Sing-Ting Wang, Wei-Chih Liao, Chia-Hung Chen, Chih-Yen Tu, Hung-Jen Chen, Te-Chun Hsia, Wen-Chien Cheng
BMC Cancer.2022;[Epub] CrossRef
State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan
Yung-Hung Luo, Kung-Hao Liang, Hsu-Ching Huang, Chia-I Shen, Chi-Lu Chiang, Mong-Lien Wang, Shih-Hwa Chiou, Yuh-Min Chen
International Journal of Molecular Sciences.2022; 23(13): 7037. CrossRef
Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study
Suey-Haur Lee, Yu-Ching Lin, Li-Chung Chiu, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Shih-Hong Li, Yueh-Fu Fang, Chih-Hung Chen, Scott Chih-Hsi Kuo, Chin-Chou Wang, Cheng-Ta Yang, Ping-Chih Hsu
Therapeutic Advances in Medical Oncology.2022;[Epub] CrossRef
The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials
Bi-Cheng Wang, Wen-Xuan Zhang, Bo-Hua Kuang, Guo-He Lin, Alessandro Rizzo
PLOS ONE.2022; 17(10): e0275919. CrossRef

8,991 View
268 Download
10 Web of Science
12 Crossref

Case Report

A Case of Simultaneously Diagnosed Lung Adenocarcinoma and Endobronchial Inflammatory Myofibroblastic Tumor with Two Distinct Types of ALK Translocation: Shikang Zhao, Wei Liu, Shuo Li, Tao Shi, Qiusong Chen, Qi Li, Leina Sun, Dian Ren, Zuoqing Song, Chun Huang, Song Xu; Cancer Res Treat. 2021;53(2):601-606. Published online October 21, 2020; DOI: https://doi.org/10.4143/crt.2020.952

Abstract PDF PubReader ePub

A 61-year-old male patient was simultaneously diagnosed with lung adenocarcinoma and inflammatory myofibroblastic tumor (IMT). The lung adenocarcinoma and IMT harbored two distinct types of ALK translocation, LOC101927285-ALK, and TPM3-ALK, respectively. The ALK Ventana showed strong positivity on both lesions. The patient was therefore given an endobronchial cryotherapy and ALK inhibitor crizotinib. The tumors showed durable response however the left lung adenocarcinoma relapsed at 17th month post-crizotinib treatment. Tissue re-biopsy on the resistant tumor revealed an ALK exon 23 C1156Y missense mutation in addition to LOC101927285-ALK mutation. Further RNA-based sequence uncovered that the noncoding region rearrangement is the fusion mutation of EML4-ALK. The patient was therefore received alectinib, and the tumor exhibited partly response. Overall, it is very rare that two types of pulmonary tumors exist in one patient driven by two distinct ALK fusions, which emphasizes the necessity of gene sequencing in clinical decision-making and individualized therapy.

Citations

Citations to this article as recorded by

TTC7A-ALK, a novel ALK fusion variant identified in a patient with metastatic lung adenocarcinoma, exhibits excellent response to crizotinib
Meijin Huang, Xiangqing Zhu, Wenmang Xu, Jun Zhu, Xin Xun, Bin Su, Hong Chen
Translational Oncology.2025; 54: 102345. CrossRef
Clinicopathological analysis of 18 cases of inflammatory myofibroblastic tumor in oral and maxillofacial region
Wei Li, Meng-chen Li, Zi-xuan Fan, Zi-chen Cao, Jie Yang, Xu-dong Yang, Xiao-feng Huang
BMC Oral Health.2025;[Epub] CrossRef
Retroperitoneal invasive fibromatosis after laparoscopic radical resection of colon cancer: a case report and literature review
Tiantian Shan, Yiqi Zhang, Yang Yao, Min Li, Xiaoying Li
Frontiers in Oncology.2025;[Epub] CrossRef
Successful treatment of a non‐small‐cell lung cancer patient harboring HIP1‐ALK (H28:A20) and CTNNB1 p.S45del with alectinib
Vito Longo, Francesco Pesola, Rosanna Lacalamita, Annamaria Catino, Michele Montrone, Ilaria Marech, Pamela Pizzutilo, Elisabetta Sara Montagna, Stefania Tommasi, Domenico Galetta
Thoracic Cancer.2024; 15(31): 2283. CrossRef
Coexistence of a novel SV2B-ALK, EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review
Huang Chen, Menglan Zhang, Liyan Bai, Yun Niu, Xiaowei Wang, Ruiying Jiang, Ye Wang, Qianqian Feng, Bei Wang, Tingli Dai, Mingming Yuan, Rongrong Chen, Yujuan Qi, Dingrong Zhong
Frontiers in Oncology.2024;[Epub] CrossRef
Novel treatment of endobronchial inflammatory myofibroblastic tumor in a child
Jessica Reyes‐Angel, Louis B. Rapkin, Jeffrey P. Simons, Hiren Muzumdar
Pediatric Pulmonology.2022; 57(1): 330. CrossRef
Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer
Yan Xiang, Shiyu Zhang, Xiaoxu Fang, Yingying Jiang, Tingwen Fang, Jinwen Liu, Kaihua Lu
Current Oncology.2022; 29(10): 7816. CrossRef
Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy
Jinchun Wu, Yongbin Hu, Omar Abdihamid, Gengwen Huang, Sheng Xiao, Bin Li
Frontiers in Oncology.2021;[Epub] CrossRef

7,047 View
176 Download
8 Web of Science
8 Crossref

Original Articles

Lung cancer

Genetic Alterations in Preinvasive Lung Synchronous Lesions: Soyeon Ahn, Jisun Lim, Soo Young Park, Hyojin Kim, Hyun Jung Kwon, Yeon Bi Han, Choon-Taek Lee, Sukki Cho, Jin-Haeng Chung; Cancer Res Treat. 2020;52(4):1120-1134. Published online June 5, 2020; DOI: https://doi.org/10.4143/crt.2020.307

Abstract PDF Supplementary Material PubReader ePub

Purpose
Despite advances in treatment, lung cancer remains the leading cause of cancer mortality. This study aimed to characterise genome-wide tumorigenesis events and to understand the hypothesis of the multistep carcinogenesis of lung adenocarcinoma (LUAD)
Materials and Methods
We conducted multiregion whole-exome sequencing of LUAD with synchronous atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ, or minimally invasive adenocarcinoma of 19 samples from three patients to characterize genome-wide tumorigenesis events and validate the hypothesis of the multistep carcinogenesis of LUAD. We identified potential pathogenic mutations preserved in preinvasive lesions and supplemented the finding by allelic variant level from RNA sequencing.
Results
Overall, independent mutational profiles were observed per patient and between patients. Some shared mutations including epidermal growth factor receptor (EGFR , p.L858R) were present across synchronous lesions.
Conclusion
Here, we show that there are driver gene mutations in AAH, and they may exacerbate as a sequence in a histological continuum, supporting the Darwinian evolution model of cancer genome. The intertumoral and intratumoral heterogeneity of synchronous LUAD implies that multi-biomarker strategies might be necessary for appropriate treatment.

Citations

Citations to this article as recorded by

Gene Expression Profiles of Multiple Synchronous Lesions in Lung Adenocarcinoma
Jisun Lim, Yeon Bi Han, Soo Young Park, Soyeon Ahn, Hyojin Kim, Hyun Jung Kwon, Choon-Taek Lee, Sukki Cho, Jin-Haeng Chung
Cells.2021; 10(12): 3484. CrossRef

9,977 View
156 Download
2 Web of Science
1 Crossref

Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea: Hee Yeon Lee, Ji Hyung Hong, Jae Ho Byun, Hee-Jun Kim, Sun Kyung Baek, Jin Young Kim, Ki Hyang Kim, Jina Yun, Jung A Kim, Kwonoh Park, Hyo Jin Lee, Jung Lim Lee, Young-Woong Won, Il Hwan Kim, Woo Kyun Bae, Kyong Hwa Park, Der-Sheng Sun, Suee Lee, Min-Young Lee, Guk Jin Lee, Sook Hee Hong, Yun Hwa Jung, Ho Jung An; Cancer Res Treat. 2020;52(1):277-283. Published online July 12, 2019; DOI: https://doi.org/10.4143/crt.2019.292

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early stage.
Materials and Methods
Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected.
Results
Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease ≤ 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence.
Conclusion
Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.

Citations

Citations to this article as recorded by

Ovarian clear cell carcinoma: open questions on the management and treatment algorithm
Roberta Rosso, Margherita Turinetto, Fulvio Borella, Nicolas Chopin, Pierre Meeus, Alexandra Lainè, Isabelle Ray-Coquard, Olivia Le Saux, Domenico Ferraioli
The Oncologist.2025;[Epub] CrossRef
The immunotherapy era in ovarian clear cell carcinoma: current evidence and future perspective
Anna Passarelli, Sabrina Chiara Cecere, Jole Ventriglia, Carmela Pisano, Rosella De Cecio, Sabrina Rossetti, Rosa Tambaro, Marilena Di Napoli, Lorenzo Lobianco, Gabriele Calvanese, Maria Rosaria Lamia, Erica Perri, Maria Sara Peluso, Emilia Scarpa, Salvat
Frontiers in Immunology.2025;[Epub] CrossRef
Patients’ knowledge, attitudes, and practices concerning endometriosis and its long-term management
Chengbin Lin, Zhiwei Wu, Yuanjun Cai
BMC Women's Health.2025;[Epub] CrossRef
From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer
Zesi Liu, Chunli Jing, Fandou Kong
Journal of Ovarian Research.2024;[Epub] CrossRef
SOX17 expression in ovarian clear cell carcinoma
Daichi Kodama, Motoki Takenaka, Chiemi Saigo, Masako Azuma, Yuki Hanamatsu, Masanori Isobe, Tamotsu Takeuchi
Journal of Ovarian Research.2024;[Epub] CrossRef
Construction of a Prediction Model of Cancer-Specific Survival after Ovarian Clear Cell Carcinoma Surgery
Mengqi Huang, Li Ling, Yanbo Liu, Yujuan Li
Clinical and Experimental Obstetrics & Gynecology.2024;[Epub] CrossRef
Patients with stage IA ovarian clear cell carcinoma do not require chemotherapy following surgery
Li Shuqing, Zhu Zhiling
Cancer Medicine.2023; 12(6): 6668. CrossRef
Clear cell carcinoma of the ovary and venous thromboembolism: a systematic review and meta-analysis
Hamidreza Didar, Farah Farzaneh, Hanieh Najafiarab, Kosar Namakin, Kimiya Gohari, Ali Sheidaei, Sepehr Ramezani
Current Medical Research and Opinion.2023; 39(6): 901. CrossRef
The Significance of Radiotherapy in Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-Analysis
Yuan Zhuang, Hua Yang
Cancer Control.2023;[Epub] CrossRef
Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer
Satoe Fujiwara
Japanese Journal of Clinical Oncology.2023; 53(8): 664. CrossRef
Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience
Yoo-Na Kim, Yun Soo Chung, Ji Hyun Lee, Eunhyang Park, Seung-Tae Lee, Sunghoon Kim, Jung-Yun Lee
Journal of Gynecologic Oncology.2023;[Epub] CrossRef
Characteristics and Prognosis of Ovarian Pure Clear Cell Carcinoma: A Retrospective Experience of 136 Patients
Yang Gao, Wei Ding, Pengpeng Qu
Clinical and Experimental Obstetrics & Gynecology.2023;[Epub] CrossRef
A clearer view on ovarian clear cell carcinoma
Aglaja De Pauw, Eline Naert, Koen Van de Vijver, Tummers Philippe, Katrien Vandecasteele, Hannelore Denys
Acta Clinica Belgica.2022; 77(4): 792. CrossRef
Friend or foe? The prognostic role of endometriosis in women with clear cell ovarian carcinoma. A UK population-based cohort study
Anastasios Tranoulis, Felicia Helena Buruiana, Bindiya Gupta, Audrey Kwong, Aarti Lakhiani, Jason Yap, Janos Balega, Kavita Singh
Archives of Gynecology and Obstetrics.2022; 305(5): 1279. CrossRef
Association Between Endometriosis and Prognosis of Ovarian Cancer: An Updated Meta-Analysis
Peng Chen, Chi-Yuan Zhang
Frontiers in Oncology.2022;[Epub] CrossRef
Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report
Abdulkarim Mohamed Farah, Shiyu Gu, Yan Jia
Medicine.2022; 101(37): e30666. CrossRef
Clear cell carcinoma of the ovary: a clinical and molecular perspective
Yasushi Iida, Aikou Okamoto, Robert L Hollis, Charlie Gourley, C Simon Herrington
International Journal of Gynecological Cancer.2021; 31(4): 605. CrossRef
Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study
Chenchen Zhu, Jing Zhu, Lili Qian, Hanyuan Liu, Zhen Shen, Dabao Wu, Weidong Zhao, Weihua Xiao, Ying Zhou
BMC Cancer.2021;[Epub] CrossRef
The oncological outcome of the patients with ovarian clear cell cancer: Platinum-based adjuvant chemotherapy is not suitable
Caner ÇAKIR, Fatih KILIÇ, Çiğdem KILIÇ, Dilek YÜKSEL, Vakkas KORKMAZ, Günsu KİMYON CÖMERT, Osman TÜRKMEN, Taner TURAN
Journal of Surgery and Medicine.2021; 5(8): 1. CrossRef
Development and validation of Nomograms for predicting overall survival and Cancer-specific survival in patients with ovarian clear cell carcinoma
Qian Chen, Shu Wang, Jing-He Lang
Journal of Ovarian Research.2020;[Epub] CrossRef

10,828 View
435 Download
24 Web of Science
20 Crossref

Pediatric Adenocarcinoma in Korea: A Multicenter Study: Hee-Beom Yang, Jung-Man Namgoong, Ki Hoon Kim, Dae Yeon Kim, Jinyoung Park, Hyun Beak Shin, Joong Kee Youn, Sanghoon Lee, Ji Won Lee, Sung Eun Jung, Jae Hee Chung, Yun-Mee Choe, Tae Gil Heo, In Geol Ho, Hyun-Young Kim; Cancer Res Treat. 2020;52(1):117-127. Published online June 3, 2019; DOI: https://doi.org/10.4143/crt.2019.092

Abstract PDF Supplementary Material PubReader ePub

Purpose
Adenocarcinoma is an extremely rare malignancy in the pediatric population. Research regarding pediatric adenocarcinoma is very rare in Korea. This study aimed to investigate the clinical features of pediatric adenocarcinomas of various primary organ sites in Korea.
Materials and Methods
Pediatric patients under 18 years, diagnosed with adenocarcinoma of various sites between January 1995 and December 2016, were included. We retrospectively reviewed patient and tumor characteristics and calculated survival estimates, reported as 5-year survival rate and 95% confidence interval.
Results
Of 80 patients (median age, 15 years; range, 10 to 17 years), 37 (46.3%) were men, and 24 (30%) had a family history of cancer or underlying disease relevant to malignancy. The cancer locations were the colon and rectum (n=32), ovaries (n=18), stomach (n=15), lung (n=4), small bowel (n=1), and other sites (n=10). Totally, 54.8% patients (42/77) had stage 3 or 4 disease. The median follow-up period was 2.0 years (range, 0 to 20.4). The 5-year overall survival estimate for all patients, and for those with stomach, colorectal, ovarian, and other cancer sites were 57.9%±11.5%, 58.2%±25.7%, 41.5%±18.2%, 87.5%±16.2%, and 64.0%±34.4%, respectively. The 5-year survival rate differed significantly between categories of adenocarcinomas into gastrointestinal (GI) (44.7%) and non-GI adenocarcinomas (78.8%) (p=0.007). The 5-year survival rate also differed significantly according to carcinoembryonic antigen level (69.3% in < 3 ng/mL, 23.8% in > 3 ng/mL; p < 0.001).
Conclusion
In pediatric patients, adenocarcinomas arise from various organs and are often diagnosed at advanced stages. Large, prospective studies for their accurate clinical characteristics and prognostic factors are needed.

Citations

Citations to this article as recorded by

Pretreatment level of circulating tumor cells is associated with lymph node metastasis in papillary thyroid carcinoma patients with ≤ 55 years old
Ming Yu, Jiaqin Deng, Yihua Gu, Yeqian Lai, Yuedong Wang
World Journal of Surgical Oncology.2025;[Epub] CrossRef
Nomogram to predict central lymph node metastasis in papillary thyroid carcinoma
Dehui Qiao, Xian Deng, Ruichen Liang, Xu Li, Rongjia Zhang, Zhi Lei, Hui Yang, Xiangyu Zhou
Clinical & Experimental Metastasis.2024; 41(5): 613. CrossRef
Artificial intelligence–based prediction of cervical lymph node metastasis in papillary thyroid cancer with CT
Cai Wang, Pengyi Yu, Haicheng Zhang, Xiao Han, Zheying Song, Guibin Zheng, Guangkuo Wang, Haitao Zheng, Ning Mao, Xicheng Song
European Radiology.2023; 33(10): 6828. CrossRef
Primary lung adenocarcinoma in three adolescent patients affected by bone sarcomas
Luisella Righi, Alberto Righi, Simona Vatrano, Ida Rapa, Angela Listì, Jasna Metovic, Michele Rocca, Mariacristina Salone, Paolo Giovenali, Angelo Sidoni, Fabrizio Tabbò, Angelo Paolo Dei Tos, Marco Volante, Mauro Papotti
Virchows Archiv.2021; 478(6): 1125. CrossRef
Case Report: Primary Bilateral Minimally Invasive Adenocarcinoma of the Lungs in an 11-Year-Old Child: A Rare Case
Xing Lei, Yongfei Zheng, Guohua Zhang, Hailan Zheng
Frontiers in Surgery.2021;[Epub] CrossRef

9,727 View
246 Download
2 Web of Science
5 Crossref

Impact of Pulmonary Tuberculosis on the EGFR Mutational Status and Clinical Outcome in Patients with Lung Adenocarcinoma: In Kyoung Hwang, Seung Sook Paik, Seung Hyeun Lee; Cancer Res Treat. 2019;51(1):158-168. Published online April 2, 2018; DOI: https://doi.org/10.4143/crt.2018.084

Abstract PDF Supplementary Material PubReader ePub

Purpose
Although it has been suggested that pulmonary tuberculosis (TB) is associated with increased risk of lung cancer, the exact mechanism is not clearly identified. We investigated the effect of pulmonary TB on the epidermal growth factor receptor (EGFR) mutational status and clinical outcome in patients with pulmonary adenocarcinoma.
Materials and Methods
We reviewed data of patients diagnosed with pulmonary adenocarcinoma harboring EGFR mutations and treated at our institution from 2008 to 2015. We divided our population into two groups: patients with pre-existing TB lesions on chest computed tomography scan (TB group) and those without the lesions (non-TB group). We compared the differences in EGFR mutational status, response to tyrosine kinase inhibitors (TKIs) and survival between the two groups.
Results
A total of 477 patients with pulmonary adenocarcinoma were analyzed. One hundred eighty-three patients (39%) had EGFR-mutated tumors and 100 (21%) patients had pre-existing TB lesions. The frequency of EGFR mutation was significantly higher in the TB group compared with the non-TB group (56% vs. 34%, p=0.038). Pre-existing TB lesions were independently associated with more frequent EGFR mutations in multivariate analysis (odds ratio, 1.43). In addition, both the progression-free survival (9.1 months vs. 11.6 months, p=0.020) and the overall survival (19.4 months vs. 24.5 months, p=0.014) after first-line EGFR-TKIs were significantly shorter in the TB group than in the non-TB group.
Conclusion
Previous pulmonary TB may be associated with more frequent EGFR mutations and poorer treatment response to EGFR-TKIs in patients with pulmonary adenocarcinoma.

Citations

Citations to this article as recorded by

A DNA Methylation Signature From Buccal Swabs to Identify Tuberculosis Infection
Lovisa Karlsson, Isabelle Öhrnberg, Shumaila Sayyab, David Martínez-Enguita, Mika Gustafsson, Patricia Espinoza, Melissa Méndez-Aranda, Cesar Ugarte-Gil, Lameck Diero, Ronald Tonui, Jakob Paues, Maria Lerm
The Journal of Infectious Diseases.2025; 231(1): e47. CrossRef
Contagious illness of tuberculosis and correlation with various types of cancer
Karthikeyan Sundaram, Venkataraman Prabhu
Medicine in Microecology.2025; 24: 100123. CrossRef
Coexistent Pulmonary Tuberculosis and Lung Cancer: An Analysis of Incidence Trends, Financial Burdens and Influencing Factors
Fei Qi, Hongjie Yang, Yi Han, Yujie Dong, Fan Zhang, Yishuo Wang, Juan Du, Yuan Gao, Xueguang Hu, Liqun Zhang, Tongmei Zhang
Cancer Innovation.2025;[Epub] CrossRef
Coexisting Lung Cancer and Pulmonary Tuberculosis: A Comprehensive Review From Incidence to Management
Wendi Zhou, Hongxu Lu, Jiamin Lin, Jialou Zhu, Jizhen Liang, Yalin Xie, Jinxing Hu, Ning Su
Cancer Reports.2025;[Epub] CrossRef
New Vistas in Mycobacterium tuberculosis Infection and Its Association with Lung Cancer Development
Kostas A. Papavassiliou, Amalia A. Sofianidi, Fotios G. Spiliopoulos, Alice G. Vassiliou, Athanasios G. Papavassiliou
Cancers.2025; 17(13): 2224. CrossRef
Real-world progression-free survival of first line afatinib patients with EGFR-mutant advanced lung adenocarcinoma: A multicentre study in Indonesia
Noni Novisari Soeroso, Elisna Syahruddin, Chaliza Soliha, Laksmi Wulandari, Ana Rima Setijadi, Sabrina Ermayanti, Suryanti Dwi Pratiwi, Andreas Infianto, Novita Andayani, Sri Melati Munir, Avissena Dutha Pratama, Ida Ayu Jasminarti Dwi Kusumawardani, Hary
Cancer Treatment and Research Communications.2025; 44: 100979. CrossRef
Tuberculosis Coinciding With Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma: A Diagnostic Conundrum
Nithiyanandan Ravi
Cureus.2025;[Epub] CrossRef
Reprogramming the host: Mycobacterium tuberculosis as a silent architect of the immuno-tumoral
Rodolfo L. Chávez-Domínguez, Martha Torres, Atziri A. Acevedo-Domínguez, Jesús A. Ibarra-Inocente, Claudia Carranza
Frontiers in Cellular and Infection Microbiology.2025;[Epub] CrossRef
Progress in mechanism-based diagnosis and treatment of tuberculosis comorbid with tumor
Chuan Wang, Rong-Qi Zou, Guo-Zhong He
Frontiers in Immunology.2024;[Epub] CrossRef
Lung cancer and pulmonary tuberculosis: key features of molecular mechanisms of concomitant disease
G. M. Agafonov, G. G. Kudriashov, U. S. Krylova, T. S. Zubareva, I. M. Kvetnoy, P. K. Yablonskiy
Uspehi fiziologičeskih nauk.2024; 55(3): 58. CrossRef
Antimicrobial peptides as drugs with double response against Mycobacterium tuberculosis coinfections in lung cancer
Giulia Polinário, Laura Maria Duran Gleriani Primo, Maiara Alane Baraldi Cerquetani Rosa, Freddy Humberto Marin Dett, Paula Aboud Barbugli, Cesar Augusto Roque-Borda, Fernando Rogério Pavan
Frontiers in Microbiology.2023;[Epub] CrossRef
Mycobacterium Tubercular Mediated Inflammation and Lung Carcinogenesis: Connecting Links
Abhay Vashishth, Mohd Shuaib, Tanya Bansal, Shashank Kumar
OBM Genetics.2023; 07(02): 1. CrossRef
Prevalence of Lung Cancer with a History of Tuberculosis
Nadira Putri Nastiti, Laksmi Wulandari, Sulistiawati Sulistiawati, Anna Febriani, Wiwin Is Effendi
Jurnal Respirasi.2023; 9(2): 87. CrossRef
Previous pulmonary tuberculosis enhances the risk of lung cancer: systematic reviews and meta-analysis
Hossein Abdeahad, Maryam Salehi, Atieh Yaghoubi, Amir Hossein Aalami, Farnoosh Aalami, Saman Soleimanpour
Infectious Diseases.2022; 54(4): 255. CrossRef
Pulmonary Tuberculosis and Risk of Lung Cancer: A Systematic Review and Meta-Analysis
Soo Young Hwang, Jong Yeob Kim, Hye Sun Lee, Sujee Lee, Dayeong Kim, Subin Kim, Jong Hoon Hyun, Jae Il Shin, Kyoung Hwa Lee, Sang Hoon Han, Young Goo Song
Journal of Clinical Medicine.2022; 11(3): 765. CrossRef
Clinical and pathological characteristics associated with the presence of the IS6110 Mycobacterim tuberculosis transposon in neoplastic cells from non-small cell lung cancer patients
Oscar Arrieta, Camilo Molina-Romero, Fernanda Cornejo-Granados, Brenda Marquina-Castillo, Alejandro Avilés-Salas, Gamaliel López-Leal, Andrés F. Cardona, Alette Ortega-Gómez, Mario Orozco-Morales, Adrián Ochoa-Leyva, Rogelio Hernandez-Pando
Scientific Reports.2022;[Epub] CrossRef
Lung cancer occurrence after an episode of tuberculosis: a systematic review and meta-analysis
Javier Cabrera-Sanchez, Vicente Cuba, Victor Vega, Patrick Van der Stuyft, Larissa Otero
European Respiratory Review.2022; 31(165): 220025. CrossRef
Proteomic profile of vitreous in patients with tubercular uveitis
Reema Bansal, Mohd M. Khan, Surendra Dasari, Indu Verma, David R. Goodlett, Nathan P. Manes, Aleksandra Nita-Lazar, Surya P. Sharma, Aman Kumar, Nirbhai Singh, Anuradha Chakraborti, Vishali Gupta, M.R. Dogra, Jagat Ram, Amod Gupta
Tuberculosis.2021; 126: 102036. CrossRef
Epidermal growth factor receptor-mutant pulmonary adenocarcinoma coexisting with tuberculosis
Ning Liu, Lingnan Zheng, Min Yu, Shuang Zhang
Medicine.2021; 100(8): e24569. CrossRef
Quantitative analysis of cell-free DNA by droplet digital PCR reveals the presence of EGFR mutations in non-malignant lung pathologies
Rajesh Venkataram, Srividya Arjuna, Giridhar Belur Hosmane, Anirban Chakraborty
Monaldi Archives for Chest Disease.2021;[Epub] CrossRef
Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
Yalin Xie, Ning Su, Wei Zhou, An Lei, Xiang Li, Weiwei Li, Zhan Huang, Wenchang Cen, Jinxing Hu
Cancer Management and Research.2021; Volume 13: 7517. CrossRef
A Case of Delayed Diagnostic Pulmonary Tuberculosis during Targeted Therapy in an EGFR Mutant Non-Small Cell Lung Cancer Patient
Caibao Jin, Bin Yang
Case Reports in Oncology.2021; 14(1): 659. CrossRef
Follow‐up of an occult tuberculosis scar cancer after resection of metastatic lesions
Mengyao Sun, Yinghui Xu, Xu Wang, Chao Sun, Ye Guo, Guoguang Shao, Zhiguang Yang, Yunpeng Liu, Peng Zhang, Shi Qiu, Kewei Ma
Thoracic Cancer.2020; 11(8): 2347. CrossRef

10,895 View
283 Download
20 Web of Science
23 Crossref

Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma: Hye Jin Kim, Mi-Suk Park, Jin Yong Lee, Kyunghwa Han, Yong Eun Chung, Jin-Young Choi, Myeong-Jin Kim, Chang Moo Kang; Cancer Res Treat. 2019;51(1):24-33. Published online February 5, 2018; DOI: https://doi.org/10.4143/crt.2017.404

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to investigate the impact of contrast enhanced pancreatic magnetic resonance imaging (MRI) in resectability and prognosis evaluation after staging computed tomography (CT) in patients with pancreatic ductal adenocarcinoma (PDA).
Materials and Methods
From January 2005 to December 2012, 298 patients were diagnosed to have potentially resectable stage PDA on CT. Patients were divided into CT+MR (patients underwent both CT and MRI; n=216) and CT only groups (n=82). Changes in resectability staging in the CT+MR group were evaluated. The overall survival was compared between the two groups. The recurrence-free survival and median time to liver metastasis after curative surgery were compared between the two groups.
Results
Staging was changed from resectable on CT to unresectable state on MRI in 14.4% of (31 of 216 patients) patients of the CT+MR group. The overall survival and recurrence-free survival rates were not significantly different between the two groups (p=0.162 and p=0.721, respectively). The median time to liver metastases after curative surgery in the CT+MR group (9.9 months) was significantly longer than that in the CT group (4.2 months) (p=0.011).
Conclusion
Additional MRI resulted in changes of resectability and treatment modifications in a significant proportion of patients who have potentially resectable state at CT and in prolonged time to liver metastases in patients after curative surgery. Additional MRI to standard staging CT can be recommended for surgical candidates of PDA.

Citations

Citations to this article as recorded by

ACR Appropriateness Criteria® Screening, Locoregional Assessment, and Surveillance of Pancreatic Ductal Adenocarcinoma: 2025 Update
Alice Fung, Atif Zaheer, Kristin K. Porter, Mustafa R. Bashir, Brooks D. Cash, E. Gabriela Chiorean, Youngjee Choi, Aslam Ejaz, Kenneth L. Gage, Gregory K. Russo, William Small, Elainea N. Smith, Kiran H. Thakrar, Abhinav Vij, Shaun A. Wahab, David H. Kim
Journal of the American College of Radiology.2025; 22(11): S610. CrossRef
Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments
Doaa Bugazia, Ebtesam Al-Najjar, Abdullah Esmail, Saifudeen Abdelrahim, Karen Abboud, Adham Abdelrahim, Godsfavour Umoru, Hashem A. Rayyan, Ala Abudayyeh, Ala-Eddin Al Moustafa, Maen Abdelrahim
Frontiers in Oncology.2024;[Epub] CrossRef
S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1
Thomas Seufferlein, Julia Mayerle, Stefan Boeck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl
Zeitschrift für Gastroenterologie.2024; 62(10): 874. CrossRef
S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1
Thomas Seufferlein, Julia Mayerle, Stefan Boeck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl
Zeitschrift für Gastroenterologie.2024; 62(10): 1724. CrossRef
Additional MRI for initial M-staging in pancreatic cancer: a cost-effectiveness analysis
Felix G. Gassert, Sebastian Ziegelmayer, Johanna Luitjens, Florian T. Gassert, Fabian Tollens, Johann Rink, Marcus R. Makowski, Johannes Rübenthaler, Matthias F. Froelich
European Radiology.2022; 32(4): 2448. CrossRef
Diagnostik beim Pankreaskarzinom – Update in der neuen Leitlinie
L. Grenacher, M. Juchems, A. G. Schreyer, J. Wessling, K. I. Ringe, W. Uhl, J. Mayerle, T. Seufferlein
Der Chirurg.2022; 93(5): 429. CrossRef
Pancreatic adenocarcinoma: imaging techniques for diagnosis and management
Jawaad Farrukh, Ravivarma Balasubramaniam, Anitha James, Sharan S Wadhwani, Raneem Albazaz
British Journal of Hospital Medicine.2022; 83(5): 1. CrossRef
S3-Leitlinie zum exokrinen Pankreaskarzinom – Kurzversion 2.0 – Dezember 2021, AWMF-Registernummer: 032/010OL
Thomas Seufferlein, Julia Mayerle, Stefan Böck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl
Zeitschrift für Gastroenterologie.2022; 60(06): 991. CrossRef
S3-Leitlinie zum exokrinen Pankreaskarzinom – Langversion 2.0 – Dezember 2021 – AWMF-Registernummer: 032/010OL
Thomas Seufferlein, Julia Mayerle, Stefan Böck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl
Zeitschrift für Gastroenterologie.2022; 60(11): e812. CrossRef
The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma
Hyungjin Rhee, Mi-Suk Park
Korean Journal of Radiology.2021; 22(1): 23. CrossRef
A Comparative Study of Survivor Outcomes between Preoperative Evaluation Using CT Alone and Combined CT and MRI in Patients with Pancreatic Ductal Adenocarcinoma
Ji Eun Lee, Seong Hyun Kim, Soon Jin Lee, Seo-Youn Choi, Sunyoung Lee, Bo Ra Lee
Journal of the Korean Society of Radiology.2021; 82(3): 638. CrossRef
СT and MRI in the assessment of resectable and borderline resectable pancreatic tumors
A. V. Kudryavtseva, S. S. Bagnenko, I. I. Dzidzawa, I. S. Zheleznyak, G. E. Trufanov, V. V. Ryazanov, V. A. Krasovskaya, A. B. Kotiv, A. D. Kazakov
Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery.2021; 26(1): 34. CrossRef
European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer
Stefano Partelli, Francesco Sclafani, Sorin Traian Barbu, Marc Beishon, Pierluigi Bonomo, Graça Braz, Filippo de Braud, Thomas Brunner, Giulia Martina Cavestro, Mirjam Crul, Maria Die Trill, Piero Ferollà, Ken Herrmann, Eva Karamitopoulou, Cindy Neuzillet
Cancer Treatment Reviews.2021; 99: 102208. CrossRef
ISOlation Procedure vs. conventional procedure during Distal Pancreatectomy (ISOP-DP trial): study protocol for a randomized controlled trial
Ken-ichi Okada, Manabu Kawai, Seiko Hirono, Masayuki Sho, Masaji Tani, Ippei Matsumoto, Suguru Yamada, Ryosuke Amano, Hirochika Toyama, Yo-ichi Yamashita, Takeshi Gocho, Kazuto Shibuya, Minako Nagai, Hiromitsu Maehira, Keiko Kamei, Go Ohira, Yoshihiro Shi
Trials.2021;[Epub] CrossRef
Management of Primary Squamous Cell Carcinoma of the Pancreas: A Case Report
Danling Guo, Chao Chen, Sangying Lv, Guanzuan Wu, Wei Shi, Huaifeng Li, Hongjie Hu
Frontiers in Surgery.2021;[Epub] CrossRef
Tumor-Specific miRNA Signatures in Combination with CA19-9 for Liquid Biopsy-Based Detection of PDAC
Min Woo Kim, Hani Koh, Jee Ye Kim, Suji Lee, Hyojung Lee, Young Kim, Ho Kyoung Hwang, Seung Il Kim
International Journal of Molecular Sciences.2021; 22(24): 13621. CrossRef
Imaging and Management of Pancreatic Cancer
Mariya Kobi, Gregory Veillette, Roshni Narurkar, David Sadowsky, Viktoriya Paroder, Chaitanya Shilagani, Anthony Gilet, Milana Flusberg
Seminars in Ultrasound, CT and MRI.2020; 41(2): 139. CrossRef
DUPLICATE: Imaging and Management of Pancreatic Cancer
Mariya Kobi, Gregory Veillette, Roshni Narurkar, David Sadowsky, Viktoriya Paroder, Chaitanya Shilagani, Anthony Gilet, Milana Flusberg
Seminars in Ultrasound, CT and MRI.2019;[Epub] CrossRef

12,058 View
319 Download
18 Web of Science
18 Crossref

The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma: Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Kun-Chieh Chen, Chia-Hung Hsu, Kang-Yi Su, Jeremy J. W. Chen, Huei-Wen Chen, Sung-Liang Yu, Tsung-Ying Yang, Gee-Chen Chang; Cancer Res Treat. 2018;50(4):1294-1303. Published online January 4, 2018; DOI: https://doi.org/10.4143/crt.2017.512

Abstract PDF Supplementary Material PubReader ePub

Purpose
The main objective of this study was to investigate the relationship among the clinical characteristics and the frequency of T790M mutation in advanced epidermal growth factor receptor (EGFR)‒mutant lung adenocarcinoma patients with acquired resistance after firstline EGFR‒tyrosine kinase inhibitor (TKI) treatment.
Materials and Methods
We enrolled EGFR-mutant stage IIIB-IV lung adenocarcinoma patients, who had progressed to prior EGFR-TKI therapy, and evaluated their rebiopsy EGFR mutation status.
Results
A total of 205 patients were enrolled for analysis. The overall T790M mutation rate of rebiopsy was 46.3%. The T790M mutation rates among patients with exon 19 deletion mutation, exon 21 L858R point mutation, and other mutations were 55.0%, 37.3%, and 27.3%, respectively. Baseline exon 19 deletion was associated with a significantly higher frequency of T790M mutation (adjusted odds ratio, 2.14; 95% confidence interval [CI], 1.20 to 3.83; p=0.010). In the exon 19 deletion subgroup, there was a greater prevalence of T790M mutation than other exon 19 deletion subtypes in patients with the Del E746-A750 mutation (61.6% vs. 40.6%; odds ratio, 2.35; 95% CI, 1.01 to 5.49; p=0.049). The progression-free survival (PFS) of first-line TKI treatment > 11 months was also associated with a higher T790M mutation rate (54.1% vs. 39.3%; adjusted odds ratio, 1.82; 95% CI, 1.02 to 3.25; p=0.044). Patients who underwent rebiopsy at metastatic sites had more chance to harbor T790M mutation (52.6% vs. 33.8%; adjusted odds ratio, 1.97; 95% CI, 1.06 to 3.67; p=0.032).
Conclusion
PFS of first-line EGFR-TKI, rebiopsy site, EGFR exon 19 deletion and its subtype Del E746- A750 mutation are associated with the frequency of T790M mutation.

Citations

Citations to this article as recorded by

Drug Resistance in Late-Stage Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Patients After First-Line Treatment with Tyrosine Kinase Inhibitors
Ching-Yi Lee, Shih-Wei Lee, Yi-Chiung Hsu
International Journal of Molecular Sciences.2025; 26(5): 2042. CrossRef
Next-Generation Sequencing: A Review of Its Transformative Impact on Cancer Diagnosis, Treatment, and Resistance Management
Alexandru Isaic, Nadica Motofelea, Teodora Hoinoiu, Alexandru Catalin Motofelea, Ioan Cristian Leancu, Emanuela Stan, Simona R. Gheorghe, Alina Gabriela Dutu, Andreea Crintea
Diagnostics.2025; 15(19): 2425. CrossRef
RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants
Kazumi Nishino, Jin-Yuan Shih, Kazuhiko Nakagawa, Martin Reck, Edward B. Garon, Michelle Carlsen, Tomoko Matsui, Carla Visseren-Grul, Ernest Nadal
JTO Clinical and Research Reports.2024; 5(2): 100624. CrossRef
Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors in Advanced Nonsmall Cell Lung Cancer Patients
Yan-Jei Tang, John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu
Journal of Cancer Research and Practice.2024; 11(1): 28. CrossRef
CRISPR-Based Fluorescent Reporter (CBFR) Assay for Sensitive, Specific, Inexpensive, and Visual Detection of a Specific EGFR Exon 19 Deletion in NSCLC
Pouya Salehipour, Mojdeh Mahdiannasser, Ghazal Sedaghat Shayegan, Kimia Shankaie, Mina Tabrizi, Majid Mojarrad, Mohammad Hossein Modarressi
Molecular Biotechnology.2023; 65(5): 807. CrossRef
Endobronchial ultrasound‐guided re‐biopsy of non–small cell lung cancer with acquired resistance after EGFR tyrosine kinase inhibitor treatment
Kyung Soo Hong, Jinmo Cho, Jong Geol Jang, Min Hye Jang, June Hong Ahn
Thoracic Cancer.2023; 14(4): 363. CrossRef
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
Chun-Ta Huang, Chih-An Lin, Te-Jen Su, Ching-Yao Yang, Tzu-Hsiu Tsai, Chia-Lin Hsu, Wei-Yu Liao, Kuan-Yu Chen, Chao-Chi Ho, Chong-Jen Yu
BMC Cancer.2023;[Epub] CrossRef
Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations
Jinfei Si, Yue Hao, Jingwen Wei, Jing Xiang, Chunwei Xu, Qiuping Shen, Zhengbo Song
BMC Pulmonary Medicine.2023;[Epub] CrossRef
FRET probe for detecting two mutations in one EGFR mRNA
Myat Thu, Kouta Yanai, Hajime Shigeto, Shohei Yamamura, Kazunori Watanabe, Takashi Ohtsuki
The Analyst.2023; 148(11): 2626. CrossRef
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
Michael J. Grant, Jacqueline V. Aredo, Jacqueline H. Starrett, Paul Stockhammer, Iris K. van Alderwerelt van Rosenburgh, Anna Wurtz, Andrew J. Piper-Valillo, Zofia Piotrowska, Christina Falcon, Helena A. Yu, Charu Aggarwal, Dylan Scholes, Tejas Patil, Chr
Clinical Cancer Research.2023; 29(11): 2123. CrossRef
NSCLC presents metabolic heterogeneity, and there is still some leeway for EGF stimuli in EGFR-mutated NSCLC
Cindy Mendes, Isabel Lemos, Inês Francisco, Teresa Almodôvar, Fernando Cunha, Cristina Albuquerque, Luís G. Gonçalves, Jacinta Serpa
Lung Cancer.2023; 182: 107283. CrossRef
Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first‐line tyrosine kinase inhibitors: A single‐center ambispective cohort study
Yangchun Gu, Jinyu Yu, Haifeng Hu, Hua Zhang, Baoshan Cao, Li Liang
Thoracic Cancer.2023; 14(31): 3147. CrossRef
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
Jia-Shiuan Ju, Allen Chung-Cheng Huang, Pi-Hung Tung, Chi-Hsien Huang, Tzu-Hsuan Chiu, Chin-Chou Wang, How-Wen Ko, Fu-Tsai Chung, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Scientific Reports.2023;[Epub] CrossRef
Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation
Chi‐Hsien Huang, Jia‐Shiuan Ju, Tzu‐Hsuan Chiu, Allen Chung‐Cheng Huang, Pi‐Hung Tung, Chin‐Chou Wang, Chien‐Ying Liu, Fu‐Tsai Chung, Yueh‐Fu Fang, Yi‐Ke Guo, Chih‐Hsi Scott Kuo, Cheng‐Ta Yang
International Journal of Cancer.2022; 150(4): 626. CrossRef
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J.W. Chen, Gee-Chen Chang
Cancer Research and Treatment.2022; 54(2): 434. CrossRef
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer
Le-Tian Huang, Shu-Ling Zhang, Cheng-Bo Han, Jie-Tao Ma
Lung Cancer.2022; 166: 9. CrossRef
Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu
Cancers.2022; 14(4): 977. CrossRef
Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer
Minehiko Inomata, Masahiro Matsumoto, Isami Mizushima, Kana Hayashi, Zenta Seto, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Kazuyuki Tobe
The Egyptian Journal of Bronchology.2022;[Epub] CrossRef
Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Non–Small Cell Lung Cancer Patients Treated with Osimertinib
Ji Young Park, Seung Hun Jang, Chang Youl Lee, Taehee Kim, Soo Jie Chung, Ye Jin Lee, Hwan Il Kim, Joo-Hee Kim, Sunghoon Park, Yong Il Hwang, Ki-Suck Jung
Tuberculosis and Respiratory Diseases.2022; 85(2): 155. CrossRef
Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
Rong Liu, Jianying Zhou, Xia Ling
Clinical Medicine Insights: Oncology.2022;[Epub] CrossRef
State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan
Yung-Hung Luo, Kung-Hao Liang, Hsu-Ching Huang, Chia-I Shen, Chi-Lu Chiang, Mong-Lien Wang, Shih-Hwa Chiou, Yuh-Min Chen
International Journal of Molecular Sciences.2022; 23(13): 7037. CrossRef
Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT)
Urška Janžič, Nina Turnšek, Mircea Dediu, Ivan Shterev Donev, Roxana Lupu, Gabriela Teodorescu, Tudor E. Ciuleanu, Adam Pluzanski
Current Oncology.2022; 29(8): 5833. CrossRef
Efficacy and Failure Patterns of Early SBRT to the Primary Tumor in Advanced EGFR-Mutation-Positive Lung Cancer with EFGR-TKI Treatment: A Prospective, Single Arm, Phase II Study
Yangyang Shi, Hailing Xu, William Y. Raynor, Jiapei Ding, Ling Lin, Chao Zhou, Wei Wang, Yinnan Meng, Xiaomai Wu, Xiaofeng Chen, Dongqing Lv, Haihua Yang
Life.2022; 12(12): 1954. CrossRef
Association of hOGG1‐Cys variants with occurrence of p53 and EGFR deletion mutations in non‐small cell lung cancer
Ming‐Jenn Chen, Ching‐Ju Shen, Lee Wang, Po‐Ming Chen, Chih‐Yi Chen, Huei Lee
Thoracic Cancer.2021; 12(4): 534. CrossRef
The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
Wen-Chien Cheng, Te-Chun Hsia, Chih-Yen Tu, Hung-Jen Chen
OncoTargets and Therapy.2021; Volume 13: 13425. CrossRef
EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis
Jeng-Shiuan Tsai, Po-Lan Su, Szu-Chun Yang, Chao-Chun Chang, Chia-Ying Lin, Yi-Ting Yen, Yau-Lin Tseng, Wu-Wei Lai, Chien-Chung Lin, Wu-Chou Su
Journal of the Formosan Medical Association.2021; 120(9): 1729. CrossRef
The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Tsung-Ying Yang, Gee-Chen Chang
Scientific Reports.2021;[Epub] CrossRef
First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
Allen Chung-Cheng Huang, Chi-Hsien Huang, Jia-Shiuan Ju, Tzu-Hsuan Chiu, Pi-Hung Tung, Chin-Chou Wang, Chien-Ying Liu, Fu-Tsai Chung, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Therapeutic Advances in Medical Oncology.2021;[Epub] CrossRef
Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
Po-Yen Chen, Chin-Chou Wang, Chien-Ning Hsu, Chung-Yu Chen
Frontiers in Pharmacology.2021;[Epub] CrossRef
Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer
Xinying Li, Cen Chen, Zimu Wang, Jiaxin Liu, Wei Sun, Kaikai Shen, Yanling Lv, Suhua Zhu, Ping Zhan, Tangfeng Lv, Yong Song
Cancer Cell International.2021;[Epub] CrossRef
Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience
Paola Ulivi, Elisabetta Petracci, Matteo Canale, Ilaria Priano, Laura Capelli, Daniele Calistri, Elisa Chiadini, Paola Cravero, Alice Rossi, Angelo Delmonte, Lucio Crinò, Giuseppe Bronte
Biomedicines.2021; 9(10): 1299. CrossRef
Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non–small cell lung cancer patients
Po-Hsin Lee, Kun-Chieh Chen, Kuo-Hsuan Hsu, Yen-Hsiang Huang, Jeng-Sen Tseng, Tsung-Ying Yang, Gee-Chen Chang
Anti-Cancer Drugs.2021; 32(10): 1099. CrossRef
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy
Alessandro Dal Maso, Martina Lorenzi, Elisa Roca, Sara Pilotto, Marianna Macerelli, Valentina Polo, Fabiana Letizia Cecere, Alessandro Del Conte, Giorgia Nardo, Vanessa Buoro, Daniela Scattolin, Sara Monteverdi, Loredana Urso, Elisabetta Zulato, Stefano F
Clinical Lung Cancer.2020; 21(1): 1. CrossRef
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
Ching-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, Kuan-Yu Chen, Tzu-Hsiu Tsai, Chia-Lin Hsu, Kang-Yi Su, Yih-Leong Chang, Chen-Tu Wu, Chia-Chi Hsu, Bin-Chi Liao, Wei-Hsun Hsu, Jih-Hsiang Lee, Chia-Chi Lin, Jin-Yuan Shih, James C.-H. Yang, Chong-Jen Yu
European Journal of Cancer.2020; 124: 110. CrossRef
Comparison detection methods for EGFR in formalin-fixed paraffin-embedded tissues of patients with NSCLC
Xiaojie Fan, Xiaoxiao Wang, Meng Zhang, Huiyan Deng, Yueping Liu
Pathology - Research and Practice.2020; 216(1): 152783. CrossRef
Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation
Sang Hoon Lee, Eun Young Kim, Arum Kim, Yoon Soo Chang
Cancer Biology & Therapy.2020; 21(8): 741. CrossRef
Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI
Chi-Lu Chiang, Hsu-Ching Huang, Chia-I Shen, Yung-Hung Luo, Yuh-Min Chen, Chao-Hua Chiu
Targeted Oncology.2020; 15(4): 503. CrossRef
An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
Shang-Gin Wu, Chi-Lu Chiang, Chien-Ying Liu, Chin-Chou Wang, Po-Lan Su, Te-Chun Hsia, Jin-Yuan Shih, Gee-Chen Chang
Frontiers in Oncology.2020;[Epub] CrossRef
Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment
Jianchun Duan, JiaChen Xu, Zhijie Wang, Hua Bai, Ying Cheng, Tongtong An, Hongjun Gao, Kai Wang, Qing Zhou, Yanping Hu, Yong Song, Cuimin Ding, Feng Peng, Li Liang, Yi Hu, Cheng Huang, Caicun Zhou, Yuankai Shi, Jiefei Han, Di Wang, Yanhua Tian, Zhenlin Ya
Journal of Thoracic Oncology.2020; 15(12): 1857. CrossRef
A Highly Sensitive Next-Generation Sequencing-Based Genotyping Platform for EGFR Mutations in Plasma from Non-Small Cell Lung Cancer Patients
Jung-Young Shin, Jeong-Oh Kim, Mi-Ran Lee, Seo Ree Kim, Kyongmin Sarah Beck, Jin Hyoung Kang
Cancers.2020; 12(12): 3579. CrossRef
Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy
Minehiko Inomata, Kenji Azechi, Naoki Takata, Kana Hayashi, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Kazuyuki Tobe
Diagnostics.2020; 10(12): 1006. CrossRef
Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
Jiyun Lee, Joon Ho Shim, Woong-Yang Park, Hee Kyung Kim, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Research and Treatment.2019; 51(1): 408. CrossRef
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations
Yen‐Ting Lin, Jin‐Shing Chen, Wei‐Yu Liao, Chao‐Chi Ho, Chia‐Lin Hsu, Ching‐Yao Yang, Kuan‐Yu Chen, Jih‐Hsiang Lee, Zhong‐Zhe Lin, Jin‐Yuan Shih, James Chih‐Hsin Yang, Chong‐Jen Yu
International Journal of Cancer.2019; 144(11): 2887. CrossRef
Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib
Chih-Hsi Scott Kuo, Chi-Hsien Huang, Chien-Ying Liu, Stelios Pavlidis, Ho-Wen Ko, Fu-Tsai Chung, Tin-Yu Lin, Chih-Liang Wang, Yi-Ke Guo, Cheng-Ta Yang
Targeted Oncology.2019; 14(4): 433. CrossRef
Frecuencia de mutación T790M determinada por biopsia líquida en pacientes con cáncer pulmonar de células no pequeñas después de la progresión a inhibidores de tirosina cinasa contra EGFR en primera línea
Jorge Arturo Alatorre-Alexander, Patricio Santillán-Doherty, María del Rosario Flores-Soto, Luis Manuel Martínez-Barrera, Jerónimo Rafael Rodríguez-Cid, Carla Paola Sánchez-Ríos
NCT Neumología y Cirugía de Tórax.2019; 78(4): 348. CrossRef

14,103 View
603 Download
53 Web of Science
45 Crossref

Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment: Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kuo-Hsuan Hsu, Yen-Hsiang Huang, Kang-Yi Su, Sung-Liang Yu, Gee-Chen Chang; Cancer Res Treat. 2018;50(4):1164-1174. Published online December 11, 2017; DOI: https://doi.org/10.4143/crt.2017.460

Abstract PDF Supplementary Material PubReader ePub

Purpose
Epidermal growth factor receptor (EGFR) T790M mutation serves as an important predictor of osimertinib efficacy. However, little is known about how it works among patients with various timings of T790M emergence and treatment.
Materials and Methods
Advanced EGFR-mutant lung adenocarcinoma patients with positive T790M mutation in tumor were retrospectively enrolled and observed to determine the outcomes of osimertinib treatment. We evaluated the association between patients’ characteristics and the efficacy of osimertinib treatment, particularly with respect to the timing of T790M emergence and osimertinib prescription.
Results
A total of 91 patients were enrolled, including 14 (15.4%) with primary and 77 (84.6%) with acquired T790M mutation. The objective response rate and disease controlratewere 60.9% and 85.1%, respectively. The median progression-free survival (PFS) and overall survival were 11.5 months (95% confidence interval [CI], 9.0 to 14.0) and 30.4 months (95% CI, 11.3 to 49.5), respectively. There was no significant difference in response rate and PFS between primary and acquired T790M populations. In the acquired T790M subgroup, patientswho received osimertinib after T790M had been confirmed by rebiopsy had a longer PFS than those with intercalated treatments between rebiopsy and osimertinib prescription (14.0 months [95% CI, 9.0 to 18.9] vs. 7.2 months [95% CI, 3.7 to 10.8]; adjusted hazard ratio, 0.48 [95% CI, 0.24 to 0.98; p=0.043]). Rebiopsy timing did not influence the outcome.
Conclusion
Osimertinib prescription with intercalated treatment following rebiopsy but not the timing of T790M emergence influenced the treatment outcome. We suggest that it is better to start osimertinib treatment once T790M mutation has been confirmed by biopsy.

Citations

Citations to this article as recorded by

Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer
Gee-Chen Chang, Jin-Yuan Shih, Chong-Jen Yu, Heng-Sheng Chao, Cheng-Ta Yang, Chien-Chung Lin, Jen-Yu Hung, Sheng-Yen Hsiao, Chin-Chou Wang, Chih-Feng Chian, Te-Chun Hsia, Yuh-Min Chen, Chien-Feng Li
PLOS ONE.2024; 19(5): e0303046. CrossRef
Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment
Jeng-Sen Tseng, Kuo-Hsuan Hsu, Zhe-Rong Zheng, Tsung-Ying Yang, Kun-Chieh Chen, Yen-Hsiang Huang, Kang-Yi Su, Sung-Liang Yu, Gee-Chen Chang
Oncology.2021; 99(1): 32. CrossRef
Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI
Chi-Lu Chiang, Hsu-Ching Huang, Chia-I Shen, Yung-Hung Luo, Yuh-Min Chen, Chao-Hua Chiu
Targeted Oncology.2020; 15(4): 503. CrossRef
Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib
Chih-Hsi Scott Kuo, Chi-Hsien Huang, Chien-Ying Liu, Stelios Pavlidis, Ho-Wen Ko, Fu-Tsai Chung, Tin-Yu Lin, Chih-Liang Wang, Yi-Ke Guo, Cheng-Ta Yang
Targeted Oncology.2019; 14(4): 433. CrossRef

10,721 View
269 Download
6 Web of Science
4 Crossref

EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors: Jiyoul Yang, Ok-Jun Lee, Seung-Myoung Son, Chang Gok Woo, Yusook Jeong, Yaewon Yang, Jihyun Kwon, Ki Hyeong Lee, Hye Sook Han; Cancer Res Treat. 2018;50(3):908-916. Published online September 19, 2017; DOI: https://doi.org/10.4143/crt.2017.378

Abstract PDF PubReader ePub

Purpose
Malignant pleural effusions (MPEs) are often observed in lung cancer, particularly adenocarcinoma. The aim of this study was to investigate epidermal growth factor receptor (EGFR) mutation status in lung adenocarcinoma-associated MPEs (LA-MPEs) and its correlation with efficacy of EGFR tyrosine kinase inhibitor (TKI) therapy.
Materials and Methods
Samples comprised 40 cell blocks of pathologically-confirmed LA-MPEs collected before the start of EGFR TKI therapy. EGFR mutation status was re-evaluated by peptide nucleic acid clamping and the clinical outcomes of EGFR TKI‒treated patients were analyzed retrospectively.
Results
EGFR mutations were detected in 72.5% of LA-MPE cell blocks (29/40). The median progression-free survival for patients with EGFR mutations in LA-MPEs was better than that for patients with wild-type EGFR (7.33 months vs. 2.07 months; hazard ratio, 0.486; 95% confidence interval, 0.206 to 1.144; p=0.032). The objective response rate (ORR) of 26 patients with EGFR mutations in LA-MPEs among the 36 patients with measurable lesions was 80.8%, while the ORR of the 10 patients with wild-type EGFR in LA-MPEs was 10% (p < 0.001). Among the 26 patients with EGFR mutations in LA-MPEs, the ORR of target lesions and LA-MPEs were 88.5% and 61.5%, respectively (p=0.026).
Conclusion
EGFR mutation status in cell blocks of LA-MPEs confirmed by pathologic diagnosis is highly predictive of EGFR TKI efficacy. For patients with EGFR mutations in LA-MPEs, the response to EGFR TKIs seems to be worse for pleural effusions than for solid tumors.

Citations

Citations to this article as recorded by

Cancer‐associated fibroblast‐derived colony‐stimulating factor 2 confers acquired osimertinib resistance in lung adenocarcinoma via promoting ribosome biosynthesis
Yutang Huang, Xiaoqing Wang, Chunjie Wen, Jingchan Wang, Honghao Zhou, Lanxiang Wu
MedComm.2024;[Epub] CrossRef
Effect of chemotherapy, immunotherapy, and targeted therapies on removal of indwelling pleural catheters in non-small cell lung cancer patients with malignant pleural effusions
Melissa Wang, Kaitlin Sparrow, Chrystal Chan, Ashley Gillson, Daniel Stollery, Pen Li
Respiratory Medicine.2023; 206: 107093. CrossRef
Malignant pleural effusion diagnosis and therapy
Liangliang Yang, Yue Wang
Open Life Sciences.2023;[Epub] CrossRef
Failure pattern and radiotherapy exploration in malignant pleural effusion non-small cell lung cancer treated with targeted therapy
Qingsong Li, Cheng Hu, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Huiqin Li, Bing Lu
Frontiers in Oncology.2023;[Epub] CrossRef
Impact of thoracic tumor radiotherapy on survival in non‐small‐cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study
Qingsong Li, Cheng Hu, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Haijie Jin, Huiqin Li, Bing Lu
Cancer Medicine.2023; 12(14): 14949. CrossRef
EGFR Mutation is a Prognostic Factor in Lung Cancer Patients with Pleural Dissemination Detected During or After Surgery
Toshiya Fujiwara, Kazuhiko Shien, Motoki Matsuura, Junichi Soh, Hiromasa Yamamoto, Soshi Takao, Yuho Maki, Tsuyoshi Ueno, Ryujiro Sugimoto, Ken Suzawa, Mikio Okazaki, Hiroyuki Tao, Makio Hayama, Masafumi Kataoka, Yoshifumi Sano, Hidetoshi Inokawa, Motohir
Annals of Surgical Oncology.2023; 30(11): 6697. CrossRef
Efficacy of hyperthermic intrathoracic chemotherapy for initially diagnosed lung cancer with symptomatic malignant pleural effusion
Zihui Li, Jie Deng, Fei Yan, Li Liu, Yanling Ma, Jianhai Sun
Scientific Reports.2023;[Epub] CrossRef
Establishment of prognostic nomograms for predicting the progression free survival of EGFR‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs
Xinyang Du, Hua Bai, Zhijie Wang, Jianchun Daun, Zheng Liu, Jiachen Xu, Geyun Chang, Yixiang Zhu, Jie Wang
Thoracic Cancer.2022; 13(9): 1289. CrossRef
Clinical features and prognosis according to genomic mutations in primary and metastatic lesions of non‐small‐cell lung cancer
Wei Zhang, Wenjuan Han, Bo Yu, Xin Zhao, Gaojun Lu, Wendy Wu, Yi Zhang
Thoracic Cancer.2022; 13(11): 1642. CrossRef
Management of Malignant Pleural Effusion: Where Are We Now?
Julien Guinde, Hervé Dutau, Philippe Astoul
Seminars in Respiratory and Critical Care Medicine.2022; 43(04): 559. CrossRef
Non-Small Cell Lung Cancer with Malignant Pleural Effusion May Require Primary Tumor Radiotherapy in Addition to Drug Treatment
Qingsong Li, Cheng Hu, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Huiqin Li, Bing Lu
Cancer Management and Research.2022; Volume 14: 3347. CrossRef
The impact of smoking status on the progression‐free survival of non‐small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta‐analysis
Xinyi Li, Cong Huang, Xiaohui Xie, Ziyang Wu, Xia Tian, Yibo Wu, Xin Du, Luwen Shi
Journal of Clinical Pharmacy and Therapeutics.2021; 46(2): 256. CrossRef
Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations
Audra J. Schwalk, David E. Ost, Sahara N. Saltijeral, Henriette De La Garza, Roberto F. Casal, Carlos A. Jimenez, Georgie A. Eapen, Jeff Lewis, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Jack Lee, Yasir Elamin, Jianjun Zhang, Jack A. Roth, Stephen S
Chest.2021; 159(3): 1256. CrossRef
Advances in pleural infection and malignancy
Eihab O. Bedawi, Julien Guinde, Najiib M. Rahman, Philippe Astoul
European Respiratory Review.2021; 30(159): 200002. CrossRef
Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions
Maria Alba Sorolla, Anabel Sorolla, Eva Parisi, Antonieta Salud, José M. Porcel
Cancers.2021; 13(11): 2798. CrossRef
Clinical Characteristics and Therapeutic Outcomes of Metastatic Peritoneal Carcinomatosis in Non-Small-Cell Lung Cancer
Tetsuo Tani, Ichiro Nakachi, Shinnosuke Ikemura, Shigenari Nukaga, Keiko Ohgino, Aoi Kuroda, Hideki Terai, Keita Masuzawa, Taro Shinozaki, Kota Ishioka, Yohei Funatsu, Hidefumi Koh, Koichi Fukunaga, Kenzo Soejima
Cancer Management and Research.2021; Volume 13: 7497. CrossRef
LENT Score: Predicting the Survival of Malignant Pleural Effusion – A Prospective Study of Three Years
Sara Raimundo, Ana Isabel Loureiro, Fortunato Vieira, Ana Fernandes
Archivos de Bronconeumología.2020; 56(7): 465. CrossRef
Current applications of molecular testing on body cavity fluids
Daniel Pinto, Fernando Schmitt
Diagnostic Cytopathology.2020; 48(9): 840. CrossRef
Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer
Jianqiang Li, Xingliang Li, Wenxian Wang, Yang Shao, Yiping Zhang, Zhengbo Song
Translational Oncology.2020; 13(8): 100784. CrossRef
Progression of malignant pleural effusion during the early stage of gefitinib treatment in advanced EGFR-mutant lung adenocarcinoma involving complex driver gene mutations
Ning Liu, Min Yu, Tao Yin, Yong Jiang, Xuelian Liao, Jie Tang, Yanying Li, Diyuan Qin, Dan Li, Yongsheng Wang
Signal Transduction and Targeted Therapy.2020;[Epub] CrossRef
LENT Score: Predicting the Survival of Malignant Pleural Effusion – A Prospective Study of Three Years
Sara Raimundo, Ana Isabel Loureiro, Fortunato Vieira, Ana Fernandes
Archivos de Bronconeumología (English Edition).2020; 56(7): 465. CrossRef
Recent Developments in the Management of Malignant Pleural Effusions: a Narrative Review
Clifford E. Coile, Jessie G. Harvey, Michal Senitko
Current Pulmonology Reports.2020; 9(4): 164. CrossRef
Detecting EGFR mutations and ALK/ROS1 rearrangements in non‐small cell lung cancer using malignant pleural effusion samples
Yi Yao, Min Peng, Qinglin Shen, Qinyong Hu, Hongyun Gong, Qingqing Li, Zhongliang Zheng, Bin Xu, Yingge Li, Yi Dong
Thoracic Cancer.2019; 10(2): 193. CrossRef
Making cold malignant pleural effusions hot: driving novel immunotherapies
Pranav Murthy, Chigozirim N. Ekeke, Kira L. Russell, Samuel C. Butler, Yue Wang, James D. Luketich, Adam C. Soloff, Rajeev Dhupar, Michael T. Lotze
OncoImmunology.2019; 8(4): e1554969. CrossRef
Novel insights into the systemic treatment of lung cancer malignant pleural effusion
Claire Tissot, Pierre Gay, Clément Brun, Marios E. Froudarakis
The Clinical Respiratory Journal.2019; 13(3): 131. CrossRef
Proceedings of the American Society of Cytopathology companion session at the 2019 United States and Canadian Academy of Pathology Annual meeting, part 2: effusion cytology with focus on theranostics and diagnosis of malignant mesothelioma
Momin T. Siddiqui, Fernando Schmitt, Andrew Churg
Journal of the American Society of Cytopathology.2019; 8(6): 352. CrossRef

11,767 View
280 Download
35 Web of Science
26 Crossref

The Role of Consolidation Chemoradiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis: Jeffrey S. Chang, Yen-Feng Chiu, Jih-Chang Yu, Li-Tzong Chen, Hui-Ju Ch’ang; Cancer Res Treat. 2018;50(2):562-574. Published online June 9, 2017; DOI: https://doi.org/10.4143/crt.2017.105

Abstract PDF Supplementary Material PubReader ePub

Purpose
The role of consolidation chemoradiation (CCRT) after systemic chemotherapy in locally advanced pancreatic cancer (LAPC) is still controversial. We aim to evaluate the effectiveness of CCRT in LAPC using systematic review and meta-analysis of prospective studies.
Materials and Methods
Prospective clinical trials of LAPC receiving chemotherapy with or without subsequent CCRT were included in the analysis. We systematically searched in PubMed, MEDLINE, Embase, and Web of Science. The primary outcome of interest was 1-year survival. Secondary endpoints were median overall survival, progression-free survival, toxicity, and resection rate.
Results
Forty-one studies with 49 study arms were included with a total of 1,018 patients receiving CCRT after induction chemotherapy (ICT) and 954 patients receiving chemotherapy alone. CCRT after ICT did not improve 1-year survival significantly in LAPC patients compared with chemotherapy alone (58% vs. 52%). ICT lasted for at least 3 months revealed significantly improved survival of additional CCRT to LAPC patients compared to chemotherapy alone (65% vs. 52%). A marginal survival benefit of consolidation CCRT was noted in studies using maintenance chemotherapy (59% vs. 52%), and fluorouracil-based CCRT (64% vs. 52%), as well as in studies conducted after the 2010 (64% vs. 55%).
Conclusion
The survival benefit of ICT+CCRT over chemotherapy alone in treating LAPC was noted when ICT lasted for at least 3 months. Fluorouracil-based CCRT, and maintenance chemotherapy were associated with improved clinical outcomes.

Citations

Citations to this article as recorded by

Effect of Radiotherapy in Neoadjuvant Treatment of Borderline Resectable and Locally Advanced Pancreatic Cancer
Peng Tang, Junfeng Zhang, Qiang Zhou, Wenmin Yi, Huaizhi Wang
Pancreas.2025; 54(3): e246. CrossRef
Survival Benefit of Surgery versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer
Niccolò Napoli, Allegra Ripolli, Emanuele F. Kauffmann, Michael Ginesini, Riccardo Casadei, Roberto Coppola, Vyacheslav Egorov, Yuichi Nagakawa, Elena Rangelova, Emilio Vicente, Ugo Boggi, Sergio Alfieri, Marc G. Besselink, Olivier R. Busch, Amjad Khalil,
Annals of Surgical Oncology.2025; 32(13): 9995. CrossRef
Clinical subtypes of stage IV pancreatic ductal adenocarcinoma: a new perspective of clinical practices
Yi-Fei Zhang, Wei Gan, Wen-Quan Wang, Liang Liu
Cancer and Metastasis Reviews.2025;[Epub] CrossRef
A nomogram-based radiomics for predicting survival to concurrent chemoradiotherapy in inoperable pancreatic cancer: a dual-center cohort study
Xin Liu, Ke Su, Shanshan Du, Yanze Li, Peiping Sun, Shucheng Shen, Benzhe Liang, Jian Chen, Rui Liu, Rui Zhang, Heran Wang, Huadong Wang, Yong Yin, Zhenjiang Li
Frontiers in Immunology.2025;[Epub] CrossRef
Total Neoadjuvant Therapy in Localized Pancreatic Cancer: Is More Better?
Rita Saúde-Conde, Benjelloun El Ghali, Julie Navez, Christelle Bouchart, Jean-Luc Van Laethem
Cancers.2024; 16(13): 2423. CrossRef
Issues in the 2022 revision of the Clinical Practice Guidelines for Pancreatic Cancer -Radiotherapy-
Yoshinori ITO, Satoaki NAKAMURA, Takayuki OHGURI, Masanori SOMEYA, Makoto SHINOTO
Suizo.2023; 38(2): 121. CrossRef
Can Concurrent Chemoradiotherapy Add Meaningful Benefit in Addition to Induction Chemotherapy in the Management of Borderline Resectable and Locally Advanced Pancreatic Cancer?
Animesh Saha, Jonathan Wadsley, Bhawna Sirohi, Rebecca Goody, Alan Anthony, Karthikeyan Perumal, Danny Ulahanan, Fiona Collinson
Pancreas.2023; 52(1): e7. CrossRef
Predictors of Acute and Late Toxicity in Patients Receiving Chemoradiation for Unresectable Pancreatic Cancer
Rishi Das, Madeline R. Abbott, Scott W. Hadley, Vaibhav Sahai, Filip Bednar, Joseph R. Evans, Matthew J. Schipper, Theodore S. Lawrence, Kyle C. Cuneo
Advances in Radiation Oncology.2023; 8(6): 101266. CrossRef
A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study
Yung-Yeh Su, Yen-Feng Chiu, Chung-Pin Li, Shih-Hung Yang, Johnson Lin, Shyh-Jer Lin, Ping-Ying Chang, Nai-Jung Chiang, Yan-Shen Shan, Hui-Ju Ch’ang, Li-Tzong Chen
British Journal of Cancer.2022; 126(7): 1018. CrossRef
Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy
P.J. Ross, H.S. Wasan, D. Croagh, M. Nikfarjam, N. Nguyen, M. Aghmesheh, A.M. Nagrial, D. Bartholomeusz, A. Hendlisz, T. Ajithkumar, C. Iwuji, N.E. Wilson, D.M. Turner, D.C. James, E. Young, M.T. Harris
ESMO Open.2022; 7(1): 100356. CrossRef
Korean clinical practice guideline for pancreatic cancer 2021: A summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches

Pancreatology.2021; 21(7): 1326. CrossRef
Current status of non-surgical treatment of locally advanced pancreatic cancer
Stavros Spiliopoulos, Maria Teresa Zurlo, Annachiara Casella, Letizia Laera, Giammarco Surico, Alessia Surgo, Alba Fiorentino, Nicola de'Angelis, Roberto Calbi, Riccardo Memeo, Riccardo Inchingolo
World Journal of Gastrointestinal Oncology.2021; 13(12): 2064. CrossRef
Characterization of Oncolytic Vaccinia Virus Harboring the Human IFNB1 and CES2 Transgenes
Euna Cho, S M Bakhtiar Ul Islam, Fen Jiang, Ju-Eun Park, Bora Lee, Nam Deuk Kim, Tae-Ho Hwang
Cancer Research and Treatment.2020; 52(1): 309. CrossRef
ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy in unresected pancreatic cancer
Felipe A. Calvo, Marco Krengli, Jose M. Asencio, Javier Serrano, Philip Poortmans, Falk Roeder, Robert Krempien, Frank W. Hensley
Radiotherapy and Oncology.2020; 148: 57. CrossRef
Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?
Christelle Bouchart, Julie Navez, Jean Closset, Alain Hendlisz, Dirk Van Gestel, Luigi Moretti, Jean-Luc Van Laethem
Therapeutic Advances in Medical Oncology.2020;[Epub] CrossRef
Photon versus carbon ion irradiation: immunomodulatory effects exerted on murine tumor cell lines
Laura Hartmann, Philipp Schröter, Wolfram Osen, Daniel Baumann, Rienk Offringa, Mahmoud Moustafa, Rainer Will, Jürgen Debus, Stephan Brons, Stefan Rieken, Stefan B. Eichmüller
Scientific Reports.2020;[Epub] CrossRef
Contemporary management of borderline resectable pancreatic ductal adenocarcinoma
Kyriaki Lekka, Evanthia Tzitzi, Alexander Giakoustidis, Vassilios Papadopoulos, Dimitrios Giakoustidis
Annals of Hepato-Biliary-Pancreatic Surgery.2019; 23(2): 97. CrossRef
Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I‐II or unresected stage III pancreatic cancer
Sung J. Ma, Austin J. Iovoli, Gregory M. Hermann, Kavitha M. Prezzano, Anurag K. Singh
Cancer Medicine.2019; 8(9): 4110. CrossRef
Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions
Maximilian Brunner, Zhiyuan Wu, Christian Krautz, Christian Pilarsky, Robert Grützmann, Georg F. Weber
International Journal of Molecular Sciences.2019; 20(18): 4543. CrossRef

14,711 View
418 Download
21 Web of Science
19 Crossref

Effect of Adjuvant Chemotherapy after Complete Resection for Pathologic Stage IB Lung Adenocarcinoma in High-Risk Patients as Defined by a New Recurrence Risk Scoring Model: Hyo Joon Jang, Sukki Cho, Kwhanmien Kim, Sanghoon Jheon, Hee Chul Yang, Dong Kwan Kim; Cancer Res Treat. 2017;49(4):898-905. Published online January 18, 2017; DOI: https://doi.org/10.4143/crt.2016.312

Abstract PDF PubReader ePub

Purpose
We conducted a retrospective analysis to determine if adjuvant chemotherapy prolongs overall survival in patients with pathologic stage IB lung adenocarcinoma who had undergone complete resection and were defined as high-risk by a newly developed recurrence risk scoring model.
Materials and Methods
Patientswho underwent curative resection for stage IB lung adenocarcinomawere analyzed with a newly developed recurrence risk scoring model and divided into a low-risk group and a high-risk group. The patients in the high-risk group were retrospectively divided into two groups based on whether they underwent adjuvant chemotherapy or observation. Recurrence-free survival and overall survival were compared between these two groups.
Results
A total of 328 patients who underwent curative resection between 2000 and 2009 were included in this study, of whom 110 (34%) received adjuvant chemotherapy and 218 (67%) underwent observation without additional treatment. According to our risk model, 167 patients (51%) were high-risk and 161 (49%) were low-risk. The 5-year recurrence-free survival rates and overall survival were 84.4% and 91.5% in low-risk patients and 53.9% and 74.7% in high-risk patients (p < 0.001). In high-risk patients, the 5-year overall survival rates were 77% among patients who underwent observation and 87% among those who underwent adjuvant chemotherapy (p=0.019).
Conclusion
Adjuvant chemotherapy prolonged overall survival among high-risk patients who had undergone complete resection for stage IB lung adenocarcinoma.

Citations

Citations to this article as recorded by

Influence of adjuvant chemotherapy on survival for patients with completely resected high-risk stage IB NSCLC
Zi-Qing Shen, Kun-Peng Feng, Zi-Yao Fang, Tian Xia, Shu Pan, Cheng Ding, Chun Xu, Sheng Ju, Jun Chen, Chang Li, Jun Zhao
Journal of Cardiothoracic Surgery.2024;[Epub] CrossRef
Surgically Treated pT2aN0M0 (Stage IB) Non-Small Cell Lung Cancer: A 20-Year Single-Center Retrospective Study
Monica Casiraghi, Francesco Petrella, Claudia Bardoni, Shehab Mohamed, Giulia Sedda, Juliana Guarize, Antonio Passaro, Filippo De Marinis, Patrick Maisonneuve, Lorenzo Spaggiari
Journal of Clinical Medicine.2023; 12(5): 2081. CrossRef
A Novel Nomogram for Identifying Candidates for Adjuvant Chemotherapy in Patients With Stage IB Non-small Cell Lung Cancer
Xue Song, Yangyang Xie, Haoran Deng, Fei Yu, Shiqiang Wang, Yafang Lou
Cancer Control.2023;[Epub] CrossRef
Adjuvant chemotherapy may improve long-term outcomes in stage IB non-small cell lung cancer patients with previous malignancies: A propensity score-matched analysis
Ke Zhou, Yaqin Zhao, Linchuan Liang, Jie Cao, Huahang Lin, Zhiyu Peng, Jiandong Mei
Frontiers in Oncology.2022;[Epub] CrossRef
A Population-Based Study on the Prognostic factors and Efficacy of Adjuvant Chemotherapy in the Postoperative Stage for Patients with Stage IIA Non-Small Cell Lung Cancer
Wei Wang, Fei Teng, Shi Bu, Wei Xu, Qing-Chun Cai, Yue-Quan Jiang, Zhi-Qiang Wang
Risk Management and Healthcare Policy.2022; Volume 15: 1581. CrossRef
Personalized Prescription of Chemotherapy Based on Assessment of mRNA Expression of BRCA1, RRM1, ERCC1, TOP1, TOP2α, TUBβ3, TYMS, and GSTP1 Genes in Tumors Compared to Standard Chemotherapy in the Treatment of Non-Small-Cell Lung Cancer
Matvey M. Tsyganov, Evgeny O. Rodionov, Marina K. Ibragimova, Sergey V. Miller, Olga V. Cheremisina, Irina G. Frolova, Sergey A. Tuzikov, Nikolai V. Litviakov
Journal of Personalized Medicine.2022; 12(10): 1647. CrossRef
Survival Nomogram for Stage IB Non-Small-Cell Lung Cancer Patients, Based on the SEER Database and an External Validation Cohort
Zhichao Zuo, Guochao Zhang, Peng Song, Jing Yang, Shuiting Li, Zhi Zhong, Qinghao Tan, Liming Wang, Qi Xue, Shugeng Gao, Nan Sun, Jie He
Annals of Surgical Oncology.2021; 28(7): 3941. CrossRef
Drug Regimen for Patients after a Pneumonectomy
Noheul Kim, Ronny Priefer
Journal of Respiration.2021; 1(2): 114. CrossRef
Prognostic stratification of pathological node-negative lung adenocarcinoma by carcinoembryonic antigen level
Khashchuluun Batmunkh, Sukki Cho, Sungwon Yum, Kwhanmien Kim, Sanghoon Jheon
Interactive CardioVascular and Thoracic Surgery.2020; 30(6): 820. CrossRef
Effects of adjuvant chemotherapy on survival of patients with stage IB non-small cell lung cancer with visceral pleural invasion
Jun Xie, Xian Zhang, Song Hu, Wan-Da Peng, Bin Xu, Yan Li, Su-Juan Zhang, Qing Li, Chong Li
Journal of Cancer Research and Clinical Oncology.2020; 146(9): 2231. CrossRef

9,748 View
187 Download
12 Web of Science
10 Crossref

Lung Cancer Epidemiology in Korea: Aesun Shin, Chang-Mo Oh, Byung-Woo Kim, Hyeongtaek Woo, Young-Joo Won, Jin-Soo Lee; Cancer Res Treat. 2017;49(3):616-626. Published online September 23, 2016; DOI: https://doi.org/10.4143/crt.2016.178

Abstract PDF Supplementary Material PubReader ePub

Purpose
The current study was undertaken to examine the trends in the lung cancer incidence, mortality, and survival after a diagnosis in Korea.
Materials and Methods
Lung cancer incidence data according to the histologic type and mortality data were obtained from the Korea Central Cancer Registry and the Statistics Korea, respectively. The age-standardized incidence and mortality rates were calculated, and the Joinpoint model and age-period-cohort analyses were used to describe the trends in the rates. The 5-year relative survival rates of lung cancer were also calculated.
Results
Although the number of new lung cancer cases increased between 1999 and 2012, the age-standardized incidence rate decreased by 0.9% per year in men, whereas the incidence in women increased by 1.7% per year over the same time. Until 2010, the most common histologic type in men was squamous cell carcinoma, then adenocarcinoma prevailed thereafter. Since 1999, the most frequent histological type in women was adenocarcinoma. The lung cancer mortality started to decrease in 2002, with a more apparent decline for the younger age groups in both men and women. Overall, the 5-year relative survival rates have improved significantly from 11.2% for men and 14.7% for women among patients diagnosed between 1993 and 1997 to 19.3% for men and 28.2% for women among patients diagnosed between 2008 and 2012, respectively. An improvement in survival rate was observed for all major histology groups.
Conclusion
The epidemiology of lung cancer in Korea has changed over a short time span, with decreasing mortality and improving survival rates. Further study is warranted to determine the cause of these changes.

Citations

Citations to this article as recorded by

Gender Disparities and Lung Cancer Screening Outcomes Among Individuals Who Have Never Smoked
Yeon Wook Kim, Dong-Hyun Joo, So Yeon Kim, Young Sik Park, Sowon Jang, Jong Hyuk Lee, Gerard A. Silvestri, Marjolein A. Heuvelmans, Jihang Kim, Hyeontaek Hwang, Choon-Taek Lee
JAMA Network Open.2025; 8(1): e2454057. CrossRef
Spatiotemporal analysis of lung cancer mortality in Spain
Pablo Medín, Carlos M. Leveau, Javier Riancho, Ana Santurtún
Cancer Epidemiology.2025; 95: 102770. CrossRef
Association between humidifier disinfectant use and development of lung cancer: A nested case-cohort study
Soyoung Park, Yeon-Soon Ahn, Jungyun Lim, Sol Yu, Younghee Kim, Jongin Lee
Cancer Epidemiology.2025; 97: 102822. CrossRef
Chronic Obstructive Pulmonary Disease and Inhaled Treatment Effects on Mortality in Patients with Lung Cancer
Jinwoo Lee, Jiyu Sun, Hyun Woo Lee
Annals of the American Thoracic Society.2025; 22(11): 1764. CrossRef
Observed and relative survival trends of lung cancer: A systematic review of population‐based cancer registration data
Jing‐Hao Bi, Jia‐Yi Tuo, Yu‐Xuan Xiao, Dan‐Dan Tang, Xiao‐Hui Zhou, Yu‐Fei Jiang, Xiao‐Wei Ji, Yu‐Ting Tan, Hui‐Yun Yuan, Yong‐Bing Xiang
Thoracic Cancer.2024; 15(2): 142. CrossRef
Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015
Da Som Jeon, Ho Cheol Kim, Se Hee Kim, Tae-Jung Kim, Hong Kwan Kim, Mi Hyung Moon, Kyongmin Sarah Beck, Yang-Gun Suh, Changhoon Song, Jin Seok Ahn, Jeong Eun Lee, Jeong Uk Lim, Jae Hyun Jeon, Kyu-Won Jung, Chi Young Jung, Jeong Su Cho, Yoo-Duk Choi, Seung
Cancer Research and Treatment.2023; 55(1): 103. CrossRef
Incidence trends and spatial distributions of lung adenocarcinoma and squamous cell carcinoma in Taiwan
Hsin-I Liu, Chun-Ju Chiang, Shih-Yung Su, Jing-Rong Jhuang, Dai-Rong Tsai, Ya-Wen Yang, Li-Ju Lin, Yu-Chen Wang, Wen-Chung Lee
Scientific Reports.2023;[Epub] CrossRef
Problems in the Pathologic Diagnosis of Suspected Lung Cancer
Soo Han Kim, Mi-Hyun Kim, Min Ki Lee, Jung Seop Eom
Tuberculosis and Respiratory Diseases.2023; 86(3): 176. CrossRef
Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia
Ying Cheng, James Chih-Hsin Yang, Isamu Okamoto, Li Zhang, Jie Hu, Donglin Wang, Chengping Hu, Jianying Zhou, Lin Wu, Lejie Cao, Jiwei Liu, Helong Zhang, Hong Sun, Ziping Wang, Hongjun Gao, Yan Yan, Suijun Xiao, Jianxin Lin, M. Catherine Pietanza, Takayas
Immunotherapy.2023; 15(13): 1029. CrossRef
Clinical implication of the 2020 International Association for the Study of Lung Cancer histologic grading in surgically resected pathologic stage 1 lung adenocarcinomas: Prognostic value and association with computed tomography characteristics
In Sung Cho, Hyo Sup Shim, Hye-Jeong Lee, Young Joo Suh
Lung Cancer.2023; 184: 107345. CrossRef
Survival outcomes of patients with nonsmall cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors
Yeon‐Hee Baek, Eun Joo Kang, Soojung Hong, Sohee Park, Ju Hwan Kim, Ju‐Young Shin
International Journal of Cancer.2022; 150(8): 1291. CrossRef
Emerging High-Risk Population of Lung Cancer: To Reveal the Unrevealed
Fangqiu Fu, Yang Zhang, Na He, Haiquan Chen
Journal of Thoracic Oncology.2022; 17(2): e18. CrossRef
Trends in lung cancer incidence by gender, histological type and stage at diagnosis in Japan, 1993 to 2015: A multiple imputation approach
Phuong The Nguyen, Kota Katanoda, Eiko Saito, Megumi Hori, Tomio Nakayama, Tomohiro Matsuda
International Journal of Cancer.2022; 151(1): 20. CrossRef
Assessment of textbook outcome after lobectomy for early‐stage non‐small cell lung cancer in a Korean institution: A retrospective study
Woo Sik Yu, Jaeyong Shin, Jung A Son, Joonho Jung, Seokjin Haam
Thoracic Cancer.2022; 13(8): 1211. CrossRef
Exposure to Secondhand Smoke and a Tobacco-Specific Carcinogen in Non-Smokers
Jae-woo Lee, Woojung Yang, Ye-Seul Kim, Yonghwan Kim, Hyo-Sun Yoo, Hee-Taik Kang
Korean Journal of Family Medicine.2022; 43(2): 117. CrossRef
Flake Graphene-Based Nanomaterial Approach for Triggering a Ferroptosis as an Attractive Theranostic Outlook for Tackling Non-Small Lung Cancer: A Mini Review
Joanna Pancewicz, Wiesława Ewa Niklińska, Adrian Chlanda
Materials.2022; 15(10): 3456. CrossRef
Lung Cancer Patients’ Characteristics and Comorbidities Using the Korean National Hospital Discharge In-depth Injury Survey Data
Kyunghee Lee, Sunghong Kang, Jieun Hwang
Journal of Epidemiology and Global Health.2022; 12(3): 258. CrossRef
Epidemiological characteristics and risk factors of lung adenocarcinoma: A retrospective observational study from North China
Daojuan Li, Jin Shi, Xiaoping Dong, Di Liang, Jing Jin, Yutong He
Frontiers in Oncology.2022;[Epub] CrossRef
A global burden assessment of lung cancer attributed to residential radon exposure during 1990–2019
Xiaobing Shan, Xiaoyu Tian, Bo Wang, Li He, Ling Zhang, Baode Xue, Ce Liu, Ling Zheng, Yunhui Yu, Bin Luo
Indoor Air.2022;[Epub] CrossRef
Timely Assessment and Prediction of Five-Year Relative Survival of Esophageal Cancer Patients in Taizhou City, Eastern China
Yong-Ran Cheng, Zhiqiang Ling, Xiyi Jiang, Liangyou Wang, Min Zhang, Tianhui Chen, Bicheng Chen
SSRN Electronic Journal.2022;[Epub] CrossRef
Treatment Outcomes of 9,994 Patients With Extensive-Disease Small-Cell Lung Cancer From a Retrospective Nationwide Population-Based Cohort in the Korean HIRA Database
Jung Soo Lee, Seoree Kim, Soo-Yoon Sung, Yeo Hyung Kim, Hyun Woo Lee, Ji Hyung Hong, Yoon Ho Ko
Frontiers in Oncology.2021;[Epub] CrossRef
Recent Trends of Lung Cancer in Korea
Jae Guk Lee, Ho Cheol Kim, Chang-Min Choi
Tuberculosis and Respiratory Diseases.2021; 84(2): 89. CrossRef
Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study
Seo Ree Kim, Ji Hyung Hong, Soo-Yoon Sung, Yeo Hyung Kim, Sang Hoon Chun, Hyun Woo Lee, Jung Soo Lee, Yoon Ho Ko
BMC Cancer.2021;[Epub] CrossRef
Using Population-Based Cancer Registration Data and Period Analysis to Accurately Assess and Predict 5-Year Relative Survival for Lung Cancer Patients in Eastern China
Runhua Li, Min Zhang, Yongran Cheng, Xiyi Jiang, Huijuan Tang, Liangyou Wang, Tianhui Chen, Bicheng Chen
Frontiers in Oncology.2021;[Epub] CrossRef
Individual 5-Year Lung Cancer Risk Prediction Model in Korea Using a Nationwide Representative Database
Yohwan Yeo, Dong Wook Shin, Kyungdo Han, Sang Hyun Park, Keun-Hye Jeon, Jungkwon Lee, Junghyun Kim, Aesun Shin
Cancers.2021; 13(14): 3496. CrossRef
Distribution of Lung-RADS categories according to job type in a single shipyard workers
Eui Yup Chung, Young Hoo Shin, Young Wook Kim, Jun Seok Son, Chan Woo Kim, Hyoung Ouk Park, Jun Ho Lee, Seung Hyun Park, Sung Joon Woo, Chang Ho Chae
Annals of Occupational and Environmental Medicine.2021;[Epub] CrossRef
Ten-Year Trends of Clinicopathologic Features and Surgical Treatment of Lung Cancer in China
Ruochuan Zang, Ju-Fang Shi, Toni E. Lerut, Le Wang, Chia-Chuan Liu, Alessandro Brunelli, René Horsleben Petersen, Calvin Sze Hang Ng, Eric Lim, Shugeng Gao
The Annals of Thoracic Surgery.2020; 109(2): 389. CrossRef
Results of low-dose computed tomography as a regular health examination among Chinese hospital employees
Yang Zhang, Sanghoon Jheon, Huimin Li, Huibiao Zhang, Yaozeng Xie, Bin Qian, Kaihong Lin, Shengping Wang, Chen Fu, Hong Hu, Ying Zheng, Yuan Li, Haiquan Chen
The Journal of Thoracic and Cardiovascular Surgery.2020; 160(3): 824. CrossRef
Impact of Sarcopenia on Early Postoperative Complications in Early-Stage Non–Small-Cell Lung Cancer
Jiyun Lee, Seok Whan Moon, Jung Suk Choi, Kwanyong Hyun, Young Kyu Moon, Mi Hyoung Moon
The Korean Journal of Thoracic and Cardiovascular Surgery.2020; 53(3): 93. CrossRef
Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study)
Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park
Lung Cancer.2020; 146: 112. CrossRef
Patterns of percutaneous transthoracic needle biopsy (PTNB) of the lung and risk of PTNB-related severe pneumothorax: A nationwide population-based study
Bo Ram Yang, Mi-Sook Kim, Chang Min Park, Soon Ho Yoon, Kum Ju Chae, Joongyub Lee, James West
PLOS ONE.2020; 15(7): e0235599. CrossRef
Estimating the disease burden of lung cancer attributable to residential radon exposure in Korea during 2006–2015: A socio-economic approach
Juhwan Noh, Heeseon Jang, Jaelim Cho, Dae Ryong Kang, Tae Hyun Kim, Dong Chun Shin, Changsoo Kim
Science of The Total Environment.2020; 749: 141573. CrossRef
Low-dose chest computed tomographic screening and invasive diagnosis of pulmonary nodules for lung cancer in never-smokers
Yeon Wook Kim, Hye-Rin Kang, Byoung Soo Kwon, Sung Yoon Lim, Yeon Joo Lee, Jong Sun Park, Young-Jae Cho, Ho Il Yoon, Kyung Won Lee, Jae Ho Lee, Choon-Taek Lee
European Respiratory Journal.2020; 56(5): 2000177. CrossRef
Clinical Characteristics and Prognostic Factors of Lung Cancer in Korea: A Pilot Study of Data from the Korean Nationwide Lung Cancer Registry
Ho Cheol Kim, Chi Young Jung, Deog Gon Cho, Jae Hyun Jeon, Jeong Eun Lee, Jin Seok Ahn, Seung Joon Kim, Yeongdae Kim, Young-Chul Kim, Jung-Eun Kim, Boram Lee, Young-Joo Won, Chang-Min Choi
Tuberculosis and Respiratory Diseases.2019; 82(2): 118. CrossRef
Identification of Serial DNA Methylation Changes in the Blood Samples of Patients with Lung Cancer
Da Hye Moon, Sung Ok Kwon, Woo Jin Kim, Yoonki Hong
Tuberculosis and Respiratory Diseases.2019; 82(2): 126. CrossRef
High Receipt of Statins Reduces the Risk of Lung Cancer in Current Smokers With Hypercholesterolemia: The National Health Insurance Service–Health Screening Cohort
Yu-Jin Kwon, Na-Young You, Jae-Woo Lee, Joungyoun Kim, Hee-Taik Kang
Clinical Lung Cancer.2019; 20(2): e177. CrossRef
Survival benefit of first-generation epidermal growth factor receptor–tyrosine kinase inhibitors in female with advanced lung cancer
Byoung Soo Kwon, Ji Hyun Park, Seulgi Kim, Sojung Park, Wonjun Ji, Woo Sung Kim, Jae Cheol Lee, Yu Rang Park, Chang-Min Choi
Tumori Journal.2019; 105(3): 216. CrossRef
Trends and Updated Statistics of Lung Cancer in Korea
Chan Kwon Park, Seung Joon Kim
Tuberculosis and Respiratory Diseases.2019; 82(2): 175. CrossRef
Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations
Yusoo Lee, Tae Min Kim, Dong-Wan Kim, Soyeon Kim, Miso Kim, Bhumsuk Keam, Ja-Lok Ku, Dae Seog Heo
Journal of Thoracic Oncology.2019; 14(9): 1556. CrossRef
The impact of systemic treatment on brain metastasis in patients with non-small-cell lung cancer: A retrospective nationwide population-based cohort study
Jung Soo Lee, Ji Hyung Hong, Der Sheng Sun, Hye Sung Won, Yeo Hyung Kim, Mi Sun Ahn, Seok Yun Kang, Hyun Woo Lee, Yoon Ho Ko
Scientific Reports.2019;[Epub] CrossRef
Volume doubling time of lung cancer detected in idiopathic interstitial pneumonia: comparison with that in chronic obstructive pulmonary disease
Cherry Kim, Sang Min Lee, Jooae Choe, Eun Jin Chae, Kyung-Hyun Do, Joon Beom Seo
European Radiology.2018; 28(4): 1402. CrossRef
Trend Analysis for the Choice and Cost of Lung Cancer Treatment in South Korea, 2003-2013
Dohun Kim, So Young Kim, Beomseok Suh, Jong Hyock Park
Cancer Research and Treatment.2018; 50(3): 757. CrossRef
Updates on Cancer Epidemiology in Korea, 2018
Sun-Seog Kweon
Chonnam Medical Journal.2018; 54(2): 90. CrossRef
The Disease Burden of Lung Cancer Attributable to Residential Radon Exposure in Korean Homes
Jong-Hun Kim, Mina Ha
Journal of Korean Medical Science.2018;[Epub] CrossRef
Real-world treatment patterns for patients 80 years and older with early lung cancer: a nationwide claims study
Kyungjong Lee, Hye Ok Kim, Hee Kyoung Choi, Gi Hyeon Seo
BMC Pulmonary Medicine.2018;[Epub] CrossRef
Comprehensive analysis of the tumor immune micro-environment in non-small cell lung cancer for efficacy of checkpoint inhibitor
Jeong-Sun Seo, Ahreum Kim, Jong-Yeon Shin, Young Tae Kim
Scientific Reports.2018;[Epub] CrossRef
Gender as an independent prognostic factor in small-cell lung cancer: Inha Lung Cancer Cohort study using propensity score matching
Jun Hyeok Lim, Jeong-Seon Ryu, Jae Hoon Kim, Hyun-Jung Kim, DaeHyung Lee, Scott M. Langevin
PLOS ONE.2018; 13(12): e0208492. CrossRef
Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients
Mi-Sook Lee, Eun Ah Jung, Sung Bin An, Yu Jin Kim, Doo-Yi Oh, Ji-Young Song, Sang-Won Um, Joungho Han, Yoon-La Choi
Cancer Research and Treatment.2017; 49(4): 1065. CrossRef
GAB2 Amplification in Squamous Cell Lung Cancer of Non-Smokers
Yu Rang Park, Soo Hyeon Bae, Wonjun Ji, Eul-Ju Seo, Jae Cheol Lee, Hyeong Ryul Kim, Se Jin Jang, Chang-Min Choi
Journal of Korean Medical Science.2017; 32(11): 1784. CrossRef
Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancer
Myung Han Hyun, Jae Sook Sung, Eun Joo Kang, Yoon Ji Choi, Kyong Hwa Park, Sang Won Shin, Sung Yong Lee, Yeul Hong Kim
Oncotarget.2017; 8(55): 94417. CrossRef

16,287 View
558 Download
50 Web of Science
50 Crossref

Clinicopathological Features of Low-Grade Thyroid-like Nasopharyngeal Papillary Adenocarcinoma: Minhua Li, Jiangguo Wei, Xiaofei Yao, Cheng Wang; Cancer Res Treat. 2017;49(1):213-218. Published online July 4, 2016; DOI: https://doi.org/10.4143/crt.2016.195

Abstract PDF PubReader ePub

Purpose
Primary low-grade thyroid-like papillary adenocarcinomas are extremely rare neoplasms that generally originate in the nasopharynx. Here, we describe a novel case of a 15-year-old Chinese girl who was diagnosed with low-grade thyroid-like papillary adenocarcinoma, including a brief review of the literature to reveal the clinicopathological features of low-grade thyroid-like nasopharyngeal papillary adenocarcinoma.
Materials and Methods
Immunohistochemistry was used to evaluate the expression of pan-cytokeratin (CKpan), cytokeratin (CK) 7, thyroid transcription factor 1 (TTF-1), vimentin, epithelial membrane antigen (EMA), thyroglobulin, CD15, S100, P40, CK20, CDX-2, glial fibrillary acidic protein (GFAP), and Ki-67. Additionally, in situ hybridization investigation was utilized to identify the presence of small Epstein-Barr virus (EBV)–encoded RNA.
Results
Histopathological analysis revealed florid proliferation of papillary structures lined by columnar epithelial cells with fibrovascular cores. Immunohistochemically, the neoplastic cells were positive for CKpan, CK7, TTF-1, vimentin, and EMA, but negative for thyroglobulin, CD15, S100, P40, CK20, CDX-2, and GFAP. The Ki-67–labeling index reached 5% in the most concentrated spot. In situ hybridization for EBV was negative.
Conclusion
Due to the distinct rarity of low-grade thyroid-like papillary adenocarcinomaswith a favorable clinical outcome, a nationwide effort to raise public awareness of this neoplasm is required.

Citations

Citations to this article as recorded by

Clinicopathologic features of thyroid-like low-grade nasopharyngeal papillary adenocarcinoma
Weiwei Chen, Jing Zhao
Asian Journal of Surgery.2024; 47(5): 2433. CrossRef
Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma: a clinicopathological and molecular study of four cases
Lei Wang, Xiao-tong Wang, Yuan Fang, Wei Qiu, Qiu-yuan Xia, Ru Fang, Qiu Rao, Hong-lin Yin
Human Pathology.2023; 134: 66. CrossRef
Epstein–Barr virus-associated poorly differentiated nasopharyngeal adenocarcinoma: a case report and literature review
Shuai Zhang, Xiao-Peng Huang, Hai-Hong Li, Ze-Tan Chen
Journal of International Medical Research.2023;[Epub] CrossRef
Nasopharyngeal Papillary Adenocarcinoma: A Cotton Swab Appearance on Computer Tomography
Jae-Hoon Lee, Jung-Hun Kown
Ear, Nose & Throat Journal.2022; 101(1): NP28. CrossRef
Cribriform adenocarcinoma of minor salivary glands presented as a nasopharyngeal tumor: A case report highlighting the significance of cytology
Olga Kuczkiewicz-Siemion, Emilia Wnuk, Monika Durzyńska
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2022; 133(4): e91. CrossRef
Genetic profile identification and clinicopathologic characteristics analysis of the thyroid-like low-grade nasopharyngeal papillary adenocarcinoma
Tiansheng Wang, Xinrong Liu, Wentao Yu, Lin Gao, Wenzhi Deng, Qiongzhi He, Feifei Liao, Ling Chu
Pathology - Research and Practice.2022; 236: 153980. CrossRef
A Rare Case of Low-grade Nasopharyngeal Papillary Adenocarcinoma in a Young Adult Woman
Yasir Nuhu Jibril, Abubakar Danjuma Salisu, Muhammad Inuwa Mustapha, Olatunde Olaniyi Abiodun Oluwafemi
Journal of West African College of Surgeons.2022; 12(1): 107. CrossRef
Endoscopic Low-Temperature Plasma Radiofrequency Ablation for Primary Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma
Qing-Yao Zhong, Qiang Sun, Zhao-Hui Liu
Ear, Nose & Throat Journal.2021; 100(7): 563. CrossRef
A novel low‐grade nasopharyngeal adenocarcinoma characterized by a GOLGB1‐BRAF fusion gene
Justin Bubola, Cristina R. Antonescu, Ilan Weinreb, David Swanson, John R. De Almeida, Christina M. MacMillan, Brendan C. Dickson
Genes, Chromosomes and Cancer.2021; 60(1): 49. CrossRef
Low-Grade Nasopharyngeal Papillary Adenocarcinoma: A Review of 28 Patients in a Single Institution
Yuting Lai, Wanpeng Li, Changwen Zhai, Xiaole Song, Jingyi Yang, Xicai Sun, Dehui Wang
Cancer Management and Research.2021; Volume 13: 1271. CrossRef
Patología del tabique nasal (a excepción de la desviación septal)
D. Malinvaud, P. Bonfils
EMC - Otorrinolaringología.2021; 50(3): 1. CrossRef
Patologia del setto nasale (deviazione del setto esclusa)
D. Malinvaud, P. Bonfils
EMC - Otorinolaringoiatria.2021; 20(3): 1. CrossRef
Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma with squamous differentiation in the posterior nasal septum
Li Yi, Honglei Liu
Medicine.2021; 100(51): e28349. CrossRef
A Case of Thyroid-like Low Grade Nasopharyngeal Papillary Adenocarcinoma of the Posterior Nasal Septum
Arisa Oguchi, Takumi Kumai, Kan Kishibe, Miki Takahara, Akihiro Katada, Tatsuya Hayashi, Yasuaki Harabuchi
Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology).2021; 60(4): 495. CrossRef
Pathologie du septum nasal (déviation septale exclue)
D. Malinvaud, P. Bonfils
EMC - Oto-rhino-laryngologie.2021; 36(2): 1. CrossRef
Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma with Biphasic Histology
Rusella Mirza, Nestor Dela Cruz, Guillermo A. Herrera
Case Reports in Pathology.2020; 2020: 1. CrossRef
Primary papillary epithelial tumour of the sella: expanding the spectrum of TTF‐1‐positive sellar lesions
F. Roncaroli, D. Chatterjee, C. Giannini, M. Pereira, S. La Rosa, J. P. Brouland, K. Gnanalingham, C. Galli, B. Fernandes, A. Lania, B. Radotra
Neuropathology and Applied Neurobiology.2020; 46(5): 493. CrossRef
Primary thyroid-like low-grade nasopharyngeal papillary adenocarcinoma in a 11-year-old male patient: The first case report in Indonesia
Emilia Theresia, Ery Kus Dwianingsih, Hanggoro Tri Rinonce, Rita Cempaka, Camelia Herdini, Irianiwati
Human Pathology: Case Reports.2020; 21: 200392. CrossRef
Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma
Li Maocai, Liu Fuxing, Li Lianqing, Gong Lili, Duan WenChao, Liu ShouZhou
Medicine.2020; 99(33): e21599. CrossRef
A Case of Low Grade Thyroid Like Nasopharyngeal Papillary Adenocarcinoma in Posterior Nasal Septum
Chang Lok Ji, Geun Hyung Park, Soo Kweon Koo, Hwaseon Lee
Journal of Clinical Otolaryngology Head and Neck Surgery.2020; 31(1): 70. CrossRef
Biphasic Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma with a Prominent Spindle Cell Component: A Case Report
Sang Hwa Lee, Hyunjin Kim, Min Ju Kim, Byungwha Kim, Hyun-Soo Kim
Diagnostics.2020; 10(5): 323. CrossRef
Clinicopathological Features of Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma: A Case Report and Review of the Literature
Hiromasa Takakura, Takeru Hamashima, Hirohiko Tachino, Akira Nakazato, Hiroshi Minato, Masakiyo Sasahara, Hideo Shojaku
Frontiers in Surgery.2020;[Epub] CrossRef
Nasopharyngeal Papillary Adenocarcinoma as a Second Head and Neck Malignancy
Aanchal Kakkar, Pirabu Sakthivel, Swati Mahajan, Alok Thakar
Head and Neck Pathology.2019; 13(4): 699. CrossRef
Thyroid-like low-grade papillary adenocarcinoma of nasopharynx
Ainaz Sourati, Mona Malekzadeh, Azadeh Rakhshan
BMJ Case Reports.2019; 12(6): e226949. CrossRef
Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma
Fengbo Huang, Xueping Xiang, Bo Hong, Jie Min, Jinfan Li
American Journal of Clinical Pathology.2019; 152(5): 582. CrossRef
Progressive Bilateral Nasal Obstruction Due to Nasopharyngeal Mass
Hyun Jin Min, Kyung Soo Kim
JAMA Otolaryngology–Head & Neck Surgery.2019; 145(10): 971. CrossRef
Clinicopathologic Characteristics of Thyroid-like Low-grade Nasopharyngeal Papillary Adenocarcinoma: A Case Report
Liang Li, Fengjuan Zhou, Fanzhong Lin, Cuihong Han
Applied Immunohistochemistry & Molecular Morphology.2019; 27(8): e81. CrossRef
The specific immunophenotypic features of nasopharyngeal carcinoma
G. A. Demyashkin, I. V. Kastyro, A. V. Sidorin, Ya. S. Borisov
Vestnik otorinolaringologii.2018; 83(5): 40. CrossRef
Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma with squamous differentiation: a novel histological finding
Takashi Oide, Osamu Kadosono, Jun Matsushima, Di Wu, Hiroaki Nagashima, Hideto Saigusa, Atsuko Masunaga, Yukio Nakatani, Kenzo Hiroshima
Human Pathology.2017; 70: 43. CrossRef
Primary thyroid-like low-grade nasopharyngeal papillary adenocarcinoma
Wan-Lin Zhang, Shuang Ma, Lauren Havrilla, Lin Cai, Cheng-Qian Yu, Shuai Shen, Hong-Tao Xu, Liang Wang, Juan-Han Yu, Xu-Yong Lin, Endi Wang, Lian-He Yang
Medicine.2017; 96(47): e8851. CrossRef

12,990 View
243 Download
29 Web of Science
30 Crossref

Venous Invasion in Colorectal Cancer: Impact of Morphologic Findings on Detection Rate: Chungsu Hwang, Sojeong Lee, Ahrong Kim, Young-Geum Kim, Sang-Jeong Ahn, Do Youn Park; Cancer Res Treat. 2016;48(4):1222-1228. Published online February 12, 2016; DOI: https://doi.org/10.4143/crt.2015.429

Abstract PDF PubReader ePub

Purpose
Venous invasion (VI) is widely accepted as a poor prognostic factor in colorectal cancer (CRC), and is indicated as a high-risk factor determining the use of adjuvant chemotherapy in CRC. However, there is marked interobserver and intraobserver variability in VI identification and marked variability in the real prevalence of VI in CRC.
Materials and Methods
We investigated the detection rate of VI in 93 consecutive cases of T3 or T4 CRC based on the following: original pathology report, review of hematoxylin and eosin (H&E) slides with attention to the “protruding tongue” and “orphan arteriole” signs, and elastic stain as the gold standard.
Results
Overall, the detection rate of VI was significantly increased as follows: 14/93 (15.1%) in the original pathology report, 38/93 (40.9%) in review of H&E slides with attention to the “protruding tongue” and “orphan arteriole” signs, and 45/93 (48.4%) using elastic stain. VI detection based on morphologic features showed 77.8% sensitivity and 91.1% specificity and showed a linear correlation (Spearman correlation coefficient, 0.727; p < 0.001) with VI detected by elastic stain. In addition, improved agreement between detection methods (detection on the basis of morphologic features, κ=0.719 vs. original pathology report, κ=0.318) was observed using kappa statistics.
Conclusion
Slide review with special attention to the “protruding tongue” and “orphan arteriole” signs could be used for better identification of VI in CRC in routine surgical practice.

Citations

Citations to this article as recorded by

Colorectal adenosquamous carcinoma: clinicopathologic analysis of two large cohorts and literature review confirm poor prognosis and reveal prognostic aspects
Raul S Gonzalez, Rachel K Horton, Xuchen Zhang, Rondell P Graham, Teri A Longacre, Anupamjit Mehrotra, Daniela S Allende, Kelsey E McHugh, Jinru Shia, Maria Westerhoff, Amitabh Srivastava, Wei Chen, Jennifer Vazzano, Paul E Swanson, Deyali Chatterjee, Has
Histopathology.2025; 86(7): 1064. CrossRef
Elastic Tissue Staining Significantly Enhances Detection of Venous Invasion Compared to Conventional H and E Staining in Colorectal, Breast and Thyroid Carcinomas
Afraa Asif, Yusra Khan, Manahel Khuram, Mohammed Khalil, Sunil Bylappa, Abid Shaheer
Biomedical and Pharmacology Journal.2025; 18(3): 2434. CrossRef
Usefulness of Elastica van Gieson staining and the number of samples prepared for venous invasion of colorectal cancer (pT2–pT4)
Kota Nakashima, Jun Akiba, Shinji Mizuochi, Masamichi Nakayama, Naohiro Yoshida, Kenichi Koushi, Takefumi Yoshida, Fumihiko Fujita, Hitoshi Obara, Tatsuyuki Kakuma, Yoshito Akagi, Hirohisa Yano
Human Pathology Reports.2023; 31: 300690. CrossRef
Routine elastin staining improves venous invasion detection in colorectal carcinoma
Hisham F. Bahmad, Ferial Alloush, Ali Salami, Rachel Sawah, Ciara Lusnia, Ekim Kilinc, Tyson Sutherland, Sarah Alghamdi, Robert J. Poppiti
Annals of Diagnostic Pathology.2023; 66: 152170. CrossRef
The Usefulness of Elastin Staining to Detect Vascular Invasion in Cancer
Jeffrey Gonzalez, Hisham F. Bahmad, Stephanie Ocejo, Alvaro Abreu, Meagan Popp, Samantha Gogola, Vielka Fernandez, Monica Recine, Robert Poppiti
International Journal of Molecular Sciences.2023; 24(20): 15264. CrossRef
Reevaluation of Venous Invasion with Elastic Tissue Stain in Colorectal Cancers
Ebru AKAY, Serdal Sadet ÖZCAN, Merve DOĞAN, Fatoş TEKELİOĞLU, Saliha KARAGÖZ EREN, Hatice KARAMAN
Sakarya Medical Journal.2022;[Epub] CrossRef
Addition of V-Stage to Conventional TNM Staging to Create the TNVM Staging System for Accurate Prediction of Prognosis in Colon Cancer: A Multi-Institutional Retrospective Cohort Study
Jung Hoon Bae, Ji Hoon Kim, Jaeim Lee, Bong-Hyeon Kye, Sang Chul Lee, In Kyu Lee, Won Kyung Kang, Hyeon-Min Cho, Yoon Suk Lee
Biomedicines.2021; 9(8): 888. CrossRef
Feasibility and Performance of Elastin Trichrome as a Primary Stain in Colorectal Cancer Resection Specimens
Sameer Shivji, Ipshita Kak, Stephanie L. Reid, Jennifer Muir, Sara Hafezi-Bakhtiari, Hector Li-Chang, Ardit Deliallisi, Ken J. Newell, Andrea Grin, James Conner, Richard Kirsch
American Journal of Surgical Pathology.2021; 45(10): 1419. CrossRef
Comparison of Vascular Invasion With Lymph Node Metastasis as a Prognostic Factor in Stage I-III Colon Cancer: An Observational Cohort Study
Jung Hoon Bae, Ji Hoon Kim, Bong-Hyeon Kye, Abdullah Al-Sawat, Chul Seung Lee, Seung-Rim Han, In Kyu Lee, Sung Hak Lee, Yoon Suk Lee
Frontiers in Surgery.2021;[Epub] CrossRef
Three-dimensional visualization of cleared human pancreas cancer reveals that sustained epithelial-to-mesenchymal transition is not required for venous invasion
Seung-Mo Hong, DongJun Jung, Ashley Kiemen, Matthias M. Gaida, Tadashi Yoshizawa, Alicia M. Braxton, Michaël Noë, Gemma Lionheart, Kiyoko Oshima, Elizabeth D. Thompson, Richard Burkhart, Pei-Hsun Wu, Denis Wirtz, Ralph H. Hruban, Laura D. Wood
Modern Pathology.2020; 33(4): 639. CrossRef
Prognostic significance of venous invasion in node‐negative head and neck squamous cell carcinoma
Arun Gopinath, Aysha Mubeen, Brett Baskovich, Ibraheem Mohammed, Raafat Makary, Erica S. Hoy, Roi Dagan, Carmen Smotherman, Shiva Gautam, Rui P. Fernandes, Anthony M. Bunnell, Phillip Pirgousis, Ahmad Alkhasawneh
Journal of Oral Pathology & Medicine.2020; 49(2): 150. CrossRef
Comparison of the efficiency of transgelin, smooth muscle myosin, and CD31 antibodies for the assessment of vascular tumor invasion and free tumor deposits in gastric, pancreatic, and colorectal adenocarcinomas
Betul Ogut, Ozgur Ekinci, Bulent Celik, EmelRodoplu Unal, Ayse Dursun
Indian Journal of Pathology and Microbiology.2020; 63(1): 25. CrossRef
Elastin and collagen IV double staining: A refined method to detect blood vessel invasion in breast cancer
Masayoshi Fujisawa, Masako Omori, Hiroyoshi Doihara, Ye‐Min Than, Hnin Wint Wint Swe, Teizo Yoshimura, Akihiro Matsukawa
Pathology International.2020; 70(9): 612. CrossRef
Incidence of extramural venous invasion in colorectal carcinoma as determined at the invasive tumor front and its prognostic impact
Klaus Dirschmid, William Sterlacci, Ewald Wöll, Peter Tschann, Michaela Rhomberg, Felix Offner
Human Pathology.2019; 86: 102. CrossRef
Why is pancreatic cancer so deadly? The pathologist's view
Ralph H Hruban, Matthias M Gaida, Elizabeth Thompson, Seung‐Mo Hong, Michaël Noë, Lodewijk AA Brosens, Martine Jongepier, G Johan A Offerhaus, Laura D Wood
The Journal of Pathology.2019; 248(2): 131. CrossRef
Rectal cancer and the pathologist
Mariana Berho, Pablo A. Bejarano
Minerva Chirurgica.2018;[Epub] CrossRef
Identifying molecular contributors to autofluorescence of neoplastic and normal colon sections using excitation-scanning hyperspectral imaging
Joshua Deal, Sam Mayes, Craig Browning, Shante Hill, Paul Rider, Carole Boudreaux, Thomas C. Rich, Silas J. Leavesley
Journal of Biomedical Optics.2018; 24(02): 1. CrossRef

14,347 View
239 Download
17 Web of Science
17 Crossref

Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study: Hee Seung Kim, Hwa-Young Choi, Maria Lee, Dong Hoon Suh, Kidong Kim, Jae Hong No, Hyun Hoon Chung, Yong Beom Kim, Yong Sang Song; Cancer Res Treat. 2016;48(1):250-258. Published online March 6, 2015; DOI: https://doi.org/10.4143/crt.2014.324

Abstract PDF PubReader ePub

Purpose
We compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125) levels, and identified the most useful marker in patients with ovarian clear cell carcinoma (OCCC).
Materials and Methods
The study included 109 patients with OCCC who did not have any inflammatory conditions except endometriosis, and underwent primary debulking surgery between 1997 and 2012. Leukocyte differential counts (neutrophil, lymphocyte, monocyte, eosinophil, basophil, and platelet), SIR markers including neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), and platelet to lymphocyte ratio (PLR), and CA-125 levels were estimated to select potential markers for clinical outcomes.
Results
Among potential markers (neutrophil, monocyte, platelet, NLR, MLR, PLR, and CA-125 levels) selected by stepwise comparison, CA-125 levels were best at predicting advanced stage disease, suboptimal debulking and platinum-resistance (cut-off values, ≥ 46.5, ≥ 11.45, and ≥ 66.4 U/mL; accuracies, 69.4%, 78.7%, and 68.5%) while PLR ≥ 205.4 predicted noncomplete response (CR; accuracy, 71.6%) most accurately. Moreover, PLR < 205.4 was an independent factor for the reduced risk of non-CR (adjusted odds ratio, 0.17; 95% confidence interval [CI], 0.04 to 0.69), and NLR < 2.8 was a favorable factor for improved progression-free survival (PFS; adjusted hazard ratio, 0.49; 95% CI, 0.25 to 0.99) despite lack of a marker for overall survival among the potential markers.
Conclusion
CA-125 levels may be the most useful marker for predicting advanced-stage disease. Suboptimal debulking and platinum-resistance, and PLR and NLR may be most effective to predict non-CR and PFS in patients with OCCC.

Citations

Citations to this article as recorded by

Ovarian clear cell carcinoma: open questions on the management and treatment algorithm
Roberta Rosso, Margherita Turinetto, Fulvio Borella, Nicolas Chopin, Pierre Meeus, Alexandra Lainè, Isabelle Ray-Coquard, Olivia Le Saux, Domenico Ferraioli
The Oncologist.2025;[Epub] CrossRef
A clinicoradiological model based on clinical and CT features for preoperative prediction of histological classification in patients with epithelial ovarian cancers: a two-center study
Jiaojiao Li, Wenjiang Wang, Bin Zhang, Xiaolong Zhu, Di Liu, Chuangui Li, Fang Wang, Shujun Cui, Zhaoxiang Ye
Abdominal Radiology.2025; 50(9): 4331. CrossRef
Methodological limitations in the diagnostic validation of P-C4BP-Rf for ovarian clear cell carcinoma versus endometrioma: addressing sample size constraints and selective bias
Meibo Chen, Shanshan Yuan
Clinica Chimica Acta.2025; 576: 120416. CrossRef
Correlation between pre-operative platelets count and serum cancer antigen-125 level in epithelial ovarian carcer
Justina Omoikhefe Alegbeleye, Celestine Osita John
Indian Journal of Obstetrics and Gynecology Research.2024; 11(1): 17. CrossRef
Trends in survival of ovarian clear cell carcinoma patients from 2000 to 2015
Bing-Qian Tian, Shu-Wen Wang, Jing-Ying Xu, San-Gang Wu, Juan Zhou
Frontiers in Oncology.2024;[Epub] CrossRef
Prognostic value of systemic inflammation response indexes obtained from the complete blood count in patients treated for advanced ovarian carcinoma in front line
Jaime Espinós, José Manuel Aramendía, Antonio González-Martín, Marta Santisteban, Luisa Sánchez, Ángel Vizcay, José Ángel Mínguez, Juan Luis Alcázar
Clinical and Translational Oncology.2024; 26(12): 3211. CrossRef
The prognostic and clinical value of neutrophil-to-lymphocyte ratio (NLR) in ovarian cancer: A systematic review and meta-analysis
Zihan Zhang, Jinghe Lang
Journal of Medical Biochemistry.2024; 43(4): 323. CrossRef
Evaluation of inflammatory mediators as predictors ofprogression-free time (PFS) in patients with ovarian cancer(HGSOC) before and during treatment
Urszula Rychlik, Wiktor Szatkowski, Andrzej Kałamacki, Aneta Janicka, Karolina Górniak, Paweł Blecharz
Diagnostyka Laboratoryjna.2024; 60(4): 231. CrossRef
Combined use of CA125, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio for the diagnosis of borderline and malignant epithelial ovarian tumors
Ke Huang, Shengjie Xu, Jiatong Wang, Lili Ge, Juan Xu, Xuemei Jia
Journal of Ovarian Research.2023;[Epub] CrossRef
Independent predictive value of blood inflammatory composite markers in ovarian cancer: recent clinical evidence and perspective focusing on NLR and PLR
Chuan-long Zhang, Xiao-chen Jiang, Yi Li, Xue Pan, Meng-qi Gao, Yan Chen, Bo Pang
Journal of Ovarian Research.2023;[Epub] CrossRef
Trends in Systemic Inflammatory Reaction (SIR) during Paclitaxel and Carboplatin Chemotherapy in Women Suffering from Epithelial Ovarian Cancer
Michal Mleko, Elzbieta Pluta, Kazimierz Pitynski, Maciej Bodzek, Andrzej Kałamacki, Dorota Kiprian, Tomasz Banas
Cancers.2023; 15(14): 3607. CrossRef
Research Progress of the Relationship between Peripheral Blood Indexes and the Diagnosis, Treatment and Prognosis of Ovarian Cancer
洁严
Advances in Clinical Medicine.2023; 13(11): 17362. CrossRef
Diagnostic significance of neutrophil to lymphocyte ratio in endometriosis: a systematic review and meta-analysis
Fatemeh Tabatabaei, Hossein Tahernia, Arshin Ghaedi, Aida Bazrgar, Shokoufeh Khanzadeh
BMC Women's Health.2023;[Epub] CrossRef
Comparison of Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio levels in ovarian cyst among epithelial ovarian cancer patients at RSUP H. Adam Malik Medan, Indonesia
Mega Sari Dewi, Roy Yustin Simanjuntak, Letta Sari Lintang, Muhammad Fahdhy, Deri Edianto, Makmur Sitepu
Majalah Obstetri & Ginekologi.2023; 31(3): 117. CrossRef
The role of IL-6/JAK2/STAT3 signaling pathway in cancers
Bei Huang, Xiaoling Lang, Xihong Li
Frontiers in Oncology.2022;[Epub] CrossRef
Evaluation of CA-125 Biomarker in Acute Appendicitis Patients: Correlation with Clinical Symptoms and Lab Results
Mojtaba Ahmadinejad, Seyed A. Hashemi, Alireza Shirzadi, Ali Soltanian, Jafar Ashrafi, Kourosh Kabir, Mahla Alizadeh
The Open Public Health Journal.2021; 14(1): 162. CrossRef
The Use of Platelet/Lymphocyte Ratio and Cancer Antigen 125 Combined with Magnetic Resonance Diffusion-Weighted Imaging in Diagnosis of Recurrent Ovarian Cancer and Neuropathic Pain
Na Wang, Cuiping Li, Yujie Yang, Yu Guan, Fengjiao Wang, Yan Wang, Wei Zhao
World Neurosurgery.2021; 149: 502. CrossRef
Role of Systemic Inflammatory Reaction in Female Genital Organ Malignancies – State of the Art
Michal Mleko, Kazimierz Pitynski, Elzbieta Pluta, Aleksandra Czerw, Katarzyna Sygit, Beata Karakiewicz, Tomasz Banas
Cancer Management and Research.2021; Volume 13: 5491. CrossRef
The diagnostic value of the combination of hemoglobin, CA199, CA125, and HE4 in endometriosis
Ting Chen, Jia‐Ling Wei, Ting Leng, Fei Gao, Shun‐yu Hou
Journal of Clinical Laboratory Analysis.2021;[Epub] CrossRef
Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer
Carolina Maria Sassu, Innocenza Palaia, Serena Maria Boccia, Giuseppe Caruso, Giorgia Perniola, Federica Tomao, Violante Di Donato, Angela Musella, Ludovico Muzii
International Journal of Molecular Sciences.2021; 22(24): 13650. CrossRef
Prognostic significance of preoperative circulating FAR and FCI scores in patients with ovarian cancer
Huige Wang, Yanjun Shen, Xiaoyan Ding, Yongfen Ding, Ling Cheng, Juan Lai
Clinica Chimica Acta.2020; 509: 252. CrossRef
Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications
Wei Chen, Siyuan Zhong, Boer Shan, Shuling Zhou, Xiaohua Wu, Huijuan Yang, Shuang Ye
Journal of Ovarian Research.2020;[Epub] CrossRef
Preoperative neutrophil-to-lymphocyte ratio predicts 30 day postoperative morbidity and survival after primary surgery for ovarian cancer
Julie My Van Nguyen, Sarah Elizabeth Ferguson, Marcus Q Bernardini, Taymaa May, Stephane Laframboise, Liat Hogen, Geneviève Bouchard-Fortier
International Journal of Gynecological Cancer.2020; 30(9): 1378. CrossRef
Sarcopenia: Clinical implications in ovarian cancer, diagnosis, etiology, and management
Aeran Seol, Se Ik Kim, Yong Sang Song
Sports Medicine and Health Science.2020; 2(4): 202. CrossRef
Associations between Blood Cell Profiles and Primary Open-Angle Glaucoma: A Retrospective Case-Control Study
Binghua Tang, Shengjie Li, Jianping Han, Wenjun Cao, Xinghuai Sun
Ophthalmic Research.2020; 63(4): 413. CrossRef
Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma
Kosuke Yoshida, Nobuhisa Yoshikawa, Akira Shirakawa, Kaoru Niimi, Shiro Suzuki, Hiroaki Kajiyama, Fumitaka Kikkawa
Journal of Gynecologic Oncology.2019;[Epub] CrossRef
Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer
Jie-Ping Chen, Qi-Dan Huang, Ting Wan, Hua Tu, Hai-Feng Gu, Jun-Ya Cao, Ji-Hong Liu
Journal of Ovarian Research.2019;[Epub] CrossRef
Pretreatment platelet‐to‐lymphocyte ratio is associated with the response to first‐line chemotherapy and survival in patients with metastatic gastric cancer
Jin Wang, Jinglei Qu, Zhi Li, Xiaofang Che, Jing Liu, Yuee Teng, Bo Jin, Mingfang Zhao, Yunpeng Liu, Xiujuan Qu
Journal of Clinical Laboratory Analysis.2018;[Epub] CrossRef
Comparison of clinical utility between neutrophil count and neutrophil–lymphocyte ratio in patients with ovarian cancer: a single institutional experience and a literature review
Naoko Komura, Seiji Mabuchi, Eriko Yokoi, Katsumi Kozasa, Hiromasa Kuroda, Tomoyuki Sasano, Yuri Matsumoto, Tadashi Kimura
International Journal of Clinical Oncology.2018; 23(1): 104. CrossRef
Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies
Zhe Zhao, Xinrui Zhao, Jingjing Lu, Jing Xue, Peishu Liu, Hongluan Mao
Archives of Gynecology and Obstetrics.2018; 297(4): 849. CrossRef
The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis
Joanna L. Sylman, Annachiara Mitrugno, Michelle Atallah, Garth W. Tormoen, Joseph J. Shatzel, Samuel Tassi Yunga, Todd H. Wagner, John T. Leppert, Parag Mallick, Owen J. T. McCarty
Frontiers in Oncology.2018;[Epub] CrossRef
Analysis of preoperative blood platelet parameters in terms of diversity of epithelial ovarian cancer
Katarzyna Bednarska, Ewa Król, Ewa Głowacka, Hanna Romanowicz, Krzysztof Szyłło, Magdalena Klink, Zofia Sułowska, Marek Nowak
Medicine.2018; 97(12): e0180. CrossRef
Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)
Alberto Farolfi, Micaela Petrone, Emanuela Scarpi, Valentina Gallà, Filippo Greco, Claudia Casanova, Lucia Longo, Gennaro Cormio, Michele Orditura, Alessandra Bologna, Laura Zavallone, Jole Ventriglia, Elisena Franzese, Vera Loizzi, Donatella Giardina, Ev
Targeted Oncology.2018; 13(4): 469. CrossRef
Prognostic Value of Serum CA19-9 and Perioperative CA-125 Levels in Ovarian Clear Cell Carcinoma
Jun Zhu, Long Jiang, Hao Wen, Rui Bi, Xiaohua Wu, Xingzhu Ju
International Journal of Gynecological Cancer.2018; 28(6): 1108. CrossRef
Prognostic Role of Neutrophil to Lymphocyte Ratio in Ovarian Cancer: A Meta-Analysis
Gaowen Chen, Lin Zhu, Yulu Yang, Yusheng Long, Xiangyuan Li, Yifeng Wang
Technology in Cancer Research & Treatment.2018;[Epub] CrossRef
Preoperative multiplication of neutrophil and monocyte counts as a prognostic factor in epithelial ovarian cancer
E Sun Paik, Minhee Shim, Hyun Jin Choi, Yoo-Young Lee, Tae-Joong Kim, Chel Hun Choi, Jeong-Won Lee, Byoung-Gie Kim, Duk-Soo Bae
Cancer Biomarkers.2017; 17(4): 419. CrossRef
Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis
Josee-Lyne Ethier, Danielle N Desautels, Arnoud J Templeton, Amit Oza, Eitan Amir, Stephanie Lheureux
Gynecologic Oncology.2017; 145(3): 584. CrossRef
The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer
Anastasia Prodromidou, Panagiotis Andreakos, Charalampos Kazakos, Dimitrios Eftimios Vlachos, Despina Perrea, Vasilios Pergialiotis
Inflammation Research.2017; 66(6): 467. CrossRef
The value of the combination of hemoglobin, albumin, lymphocyte and platelet in predicting platinum-based chemoradiotherapy response in male patients with esophageal squamous cell carcinoma
Lihong Cong, Likuan Hu
International Immunopharmacology.2017; 46: 75. CrossRef
Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis
Yanlin Luo, Hee Seung Kim, Miseon Kim, Maria Lee, Yong Sang Song
Journal of Gynecologic Oncology.2017;[Epub] CrossRef
Adipose Stromal Cells from Visceral and Subcutaneous Fat Facilitate Migration of Ovarian Cancer Cells via IL-6/JAK2/STAT3 Pathway
Boyun Kim, Hee Seung Kim, Soochi Kim, Guy Haegeman, Benjamin K. Tsang, Danny N. Dhanasekaran, Yong Sang Song
Cancer Research and Treatment.2017; 49(2): 338. CrossRef
Prognostic significance and predictors of the system inflammation score in ovarian clear cell carcinoma
Hongwei Zhang, Jiaqi Lu, Yingying Lu, Jiayi Zhou, Zehua Wang, Haiou Liu, Congjian Xu, Renato Franco
PLOS ONE.2017; 12(5): e0177520. CrossRef
Neutrophil-to-Lymphocyte Ratio Is a Potential Prognostic Biomarker in Patients with Ovarian Cancer: A Meta-Analysis
Shubo Chen, Liu Zhang, Guangyue Yan, Sijin Cheng, Abdel Hamid Fathy, Nana Yan, Yongzhao Zhao
BioMed Research International.2017; 2017: 1. CrossRef
Prognostic significance of neutrophil to lymphocyte ratio in ovarian cancer: evidence from 4,910 patients
Quan Zhou, Li Hong, Man-Zhen Zuo, Ze He
Oncotarget.2017; 8(40): 68938. CrossRef
Predictive value of systematic inflammatory response biomarkers (NLR, LMR, PLR) in patients with ovarian cancer.
Urszula Rychlik, Ewa Wójcik, Jadwiga Tarapacz, Katarzyna Brandys, Zofia Stasik, Beata Kala, Jan K. Kulpa, Wiktor Szatkowski, Paweł Blecharz, Jerzy Jakubowicz
Diagnostyka Laboratoryjna.2017; 53(3): 139. CrossRef
Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy
Yi Miao, Qin Yan, Shuangdi Li, Bilan Li, Youji Feng
Cancer Biomarkers.2016; 17(1): 33. CrossRef
Serum carbohydrate antigen 125 concentration as a superior predictor for serosal effusion at diagnosis and a prognostic factor in diffuse large B-cell lymphoma
Jia-Zhu Wu, Tian Tian, Ying Huang, Jin-Hua Liang, Yi Miao, Li Wang, Ji Xu, Xiao-Yan Qu, Lei Fan, Jian-Yong Li, Wei Xu
Cancer Biomarkers.2016; 17(2): 205. CrossRef
The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study
Huimin Bai, Guisha Sha, Meizhu Xiao, Huiqiao Gao, Dongyan Cao, Jiaxin Yang, Jie Chen, Yue Wang, Zhenyu Zhang, Keng Shen
Oncotarget.2016; 7(13): 15566. CrossRef
Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer
Ghazala Khan, Suzanne E. Brooks, Ken I. Mills, Barbara-Ann Guinn
Biomarkers in Cancer.2015; 7: BIC.S28378. CrossRef

19,162 View
174 Download
53 Web of Science
49 Crossref

Case Report

A Case Report of Partial Nephrectomy of Mucinous Cystadenocarcinoma in Kidney and Its Literature Review: Sung Han Kim, Heong Dong Yuk, Weon Seo Park, Sun Ho Kim, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung; Cancer Res Treat. 2016;48(2):838-842. Published online February 13, 2015; DOI: https://doi.org/10.4143/crt.2014.219

Abstract PDF PubReader ePub

Mucinous cystadenocarcinoma (MC) of the kidney is a rare epithelial tumor originating from the renal pelvic urothelium and few study cases have been reported. Because of the rarity of these tumors and their unknown histogenesis, its diagnosis is difficult until surgical exploration. We report here on a 55-year-old man referred to the urology department from the hepatology department because of a cystic renal mass measuring approximately 5 cm in size, which was detected incidentally under ultrasonography during the routine examination of liver. The renal mass was finally diagnosed as MC originating from kidney after partial nephrectomy and the patient still showed no evidence of recurrence until 12 months postoperatively. This is the first report on a case of renal MC in a patient who underwent partial nephrectomy. The aim of this report is to present our unusual case of MC and also review the previous literature on the pathological and radiological aspects of MC of kidney.

Citations

Citations to this article as recorded by

Mucinous adenocarcinoma in kidneys with developmental anomalies - a report of two cases
Kasi Viswanath Gali, Arun Chawla, K. R. Surag, Sunil Pillai Bhaskara, Padmaraj Hegde
BMC Urology.2024;[Epub] CrossRef
Case report and literature review: Robot-assisted laparoscopic left renal mucinous cystadenocarcinoma radical nephrectomy
Zikuan Ning, Haoxun Zhang, Bowen Wang, Yingwei Wang, Yiwen Liu, Boju Tao, Guoling Zhang, Hua Liu, Chunyang Wang
Frontiers in Surgery.2023;[Epub] CrossRef
Mucinous cystadenocarcinoma in the renal pelvis: primary or secondary? Case report and literature review
An Tamsin, Charlotte Schillebeeckx, Charlotte Van Langenhove, Kathy Vander Eeckt, Dieter Ost, Kevin Wetzels
Acta Chirurgica Belgica.2020; 120(6): 417. CrossRef

25,201 View
121 Download
6 Web of Science
3 Crossref

Original Article

Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation–Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma: Chi Hong Kim, Seung Hoon Kim, Sonya Youngju Park, Jinyoung Yoo, Sung Kyoung Kim, Hoon Kyo Kim; Cancer Res Treat. 2015;47(4):653-660. Published online January 30, 2015; DOI: https://doi.org/10.4143/crt.2014.118

Abstract PDF PubReader ePub

Purpose
Mutation-specific antibodies have recently been developed for identification of epidermal growth factor receptor (EGFR) mutations by immunohistochemistry (IHC). This study was designed to investigate whether the type of specimen (biopsy vs. resection) would make a difference in determining mutation status by IHC, and to evaluate whether biopsies are suitable for detection of mutant EGFR protein.
Materials and Methods
IHC was performed using mutation-specific antibodies for E746-A750 deletion (DEL) and L858R point mutation (L858R) in biopsies and tissue microarrays of resected tumors from 154 patients with pulmonary adenocarcinoma. Results were then compared with DNA sequencing data.
Results
Molecular-based assays detected EGFR mutations in 62 patients (40.3%), including 14 (9.1%) with DEL, and 31 (20.1%) with L858R. IHC with two mutation-specific antibodies showed a homogeneous staining pattern, and correctly identified EGFRmutation status in 89% (137/154). Overall (biopsy/resection) sensitivity, specificity, positive predictive value, and negative predictive value were 75.6% (78.3%/72.7%), 94.5% (90.9%/96.3%), 85% (78.3%/88.9%), and 90.4% (90.9%/89.7%), respectively.
Conclusion
Our data showed that IHC using EGFR mutation–specific antibodies is useful for detection of EGFRmutations with high specificity and good sensitivity not only for resection specimens but also for biopsy materials. Therefore, IHC using EGFRmutation–specific antibodies may preclude a second biopsy procedure to obtain additional tissues for identification of EGFR mutations by molecular assays in biopsies from advanced cancer, particularly when tumor cells in the samples are limited.

Citations

Citations to this article as recorded by

Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma
Masahiro Torasawa, Tatsuya Yoshida, Kouya Shiraishi, Shigehiro Yagishita, Hanako Ono, Yuji Uehara, Jun Miyakoshi, Akiko Tateishi, Yukiko Shimoda Igawa, Ryoko Inaba Higashiyama, Akifumi Mochizuki, Ken Masuda, Yuji Matsumoto, Yuki Shinno, Yusuke Okuma, Yasu
Lung Cancer.2025; 202: 108494. CrossRef
SH3 domain‑binding glutamic acid‑rich protein‑like 3 is associated with hyperglycemia and a poor outcome in Epstein‑Barr virus‑negative gastric carcinoma
Houqiang Li, Lanqing Zheng, Xia Zhang, Xunbin Yu, Guodong Zhong, Xiaoyan Chen, Xin Chen, Linying Chen
Oncology Letters.2024;[Epub] CrossRef
Induction of SUSD2 by STAT3 Activation Is Associated with Tumor Recurrence in HER2-Positive Breast Cancer
Yisun Jeong, Hyungjoo Kim, Daeun You, Soo Youn Cho, Sun Young Yoon, Seok Won Kim, Seok Jin Nam, Jeong Eon Lee, Sangmin Kim
Cells.2024; 14(1): 19. CrossRef
MEK Is a Potential Indirect Target in Subtypes of Head and Neck Cancers
Bianka Gurbi, Diána Brauswetter, Kinga Pénzes, Attila Varga, Tibor Krenács, Kornél Dános, Ede Birtalan, László Tamás, Miklós Csala
International Journal of Molecular Sciences.2023; 24(3): 2782. CrossRef
Effects of EGFR gene mutation on stage 3A lung adenocarcinomas in the clinical decision-making process for mediastinal invasive staging
İsmail Ağababaoğlu, Özgür Ömer Yıldız, Hasan Ersöz, Gökçen Şimşek, Yavuz Selim Sanisoğlu, Nurettin Karaoğlanoğlu
Medical Science and Discovery.2022; 9(1): 44. CrossRef
Dual NGS Comparative Analysis of Liquid Biopsy (LB) and Formalin-Fixed Paraffin-Embedded (FFPE) Samples of Non-Small Cell Lung Carcinoma (NSCLC)
Laura Buburuzan, Maria-Anca Zamfir (Irofei), Carmen Maria Ardeleanu, Alin Horatiu Muresan, Florina Vasilescu, Ariana Hudita, Marieta Costache, Bianca Galateanu, Alexandra Puscasu, Alexandru Filippi, Natalia Motas
Cancers.2022; 14(24): 6084. CrossRef
Role of EGFR and HER-2/NEU Expression in Gall Bladder Carcinoma (GBC)
Chhanda Das, Madhumita Mukhopadhyay, Srijana Subba, Ashis Kumar Saha, Biswanath Mukhopadhyay
Journal of Laboratory Physicians.2021; 13(01): 029. CrossRef
Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review
Jasmina Obradovic, Jovana Todosijevic, Vladimir Jurisic
Molecular Biology Reports.2021; 48(4): 3593. CrossRef
RETRACTED ARTICLE: AKT3-mediated IWS1 phosphorylation promotes the proliferation of EGFR-mutant lung adenocarcinomas through cell cycle-regulated U2AF2 RNA splicing
Georgios I. Laliotis, Evangelia Chavdoula, Maria D. Paraskevopoulou, Abdul Kaba, Alessandro La Ferlita, Satishkumar Singh, Vollter Anastas, Keith A. Nair, Arturo Orlacchio, Vasiliki Taraslia, Ioannis Vlachos, Marina Capece, Artemis Hatzigeorgiou, Dario Pa
Nature Communications.2021;[Epub] CrossRef
Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung
Moupali Ghosh, Madhumita Mukhopadhyay, Chhanda Das, Surojit Chatterjee, Bidisha Ghosh Naskar
Journal of Cancer Research and Therapeutics.2021; 17(6): 1389. CrossRef
Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets
Arutha Kulasinghe, Joanna Kapeleris, Carolina Cooper, Majid Ebrahimi Warkiani, Kenneth O’Byrne, Chamindie Punyadeera
Cancers.2019; 11(3): 380. CrossRef
Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma
Dhoha Dhieb, Imen Belguith, Laura Capelli, Elisa Chiadini, Matteo Canale, Sara Bravaccini, Ilhem Yangui, Ons Boudawara, Rachid Jlidi, Tahya Boudawara, Daniele Calistri, Leila Ammar Keskes, Paola Ulivi
Cells.2019; 8(6): 514. CrossRef
Intratumour heterogeneity of p53 expression; causes and consequences
Yuezhen Xue, Boris San Luis, David P Lane
The Journal of Pathology.2019; 249(3): 274. CrossRef
Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non–Small-cell Lung Cancer
Edward Kim, Rebecca Feldman, Ignacio I. Wistuba
Clinical Lung Cancer.2018; 19(2): 105. CrossRef
Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?
Véronique Hofman, Sandra Lassalle, Coraline Bence, Elodie Long-Mira, Sacha Nahon-Estève, Simon Heeke, Virginie Lespinet-Fabre, Catherine Butori, Marius Ilié, Paul Hofman
Cancers.2018; 10(3): 70. CrossRef
EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry
Zohra Mraihi, Jihen Ben Amar, Hend Bouacha, Soumaya Rammeh, Lamia Hila
BMC Pulmonary Medicine.2018;[Epub] CrossRef
Immunohistochemistry for EGFR Mutation Detection in Non–Small-Cell Lung Cancer
Nina Turnšek Hitij, Izidor Kern, Aleksander Sadikov, Lea Knez, Karmen Stanič, Matjaž Zwitter, Tanja Cufer
Clinical Lung Cancer.2017; 18(3): e187. CrossRef
Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer
Aeri Kim, Min Hye Jang, Soo Jung Lee, Young Kyung Bae
Journal of Breast Cancer.2017; 20(2): 150. CrossRef
Detection of epidermal growth factor receptor mutations in lung adenocarcinoma cytological specimens by immunocytochemistry
Masami Yoshida, Tadasuke Nagatomo, Takafumi Ohnishi, Mayumi Kawashima, Akira Naitoh, Eiichi Morii
Molecular and Clinical Oncology.2017;[Epub] CrossRef
Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods
Hua-Lin Kao, Yi-Chen Yeh, Chin-Hsuan Lin, Wei-Fang Hsu, Wen-Yu Hsieh, Hsiang-Ling Ho, Teh-Ying Chou
Lung Cancer.2016; 101: 40. CrossRef
LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients
Yu Jin Kim, Sungyoul Hong, Minjung Sung, Min Jeong Park, Kyungsoo Jung, Ka-Won Noh, Doo-Yi Oh, Mi-Sook Lee, Ensel Oh, Young Kee Shin, Yoon-La Choi
Oncotarget.2016; 7(50): 82876. CrossRef

16,085 View
121 Download
26 Web of Science
21 Crossref

First
Prev
Page of 3
Next
Last

Search